

1 Cytotoxic T cells are silenced to induce disease tolerance in human malaria

2 Diana Muñoz Sandoval,^{1,2*} Florian A. Bach,^{1*} Alasdair Ivens,¹ Adam C. Harding,¹ Natasha L.
3 Smith,¹ Michalina Mazurczyk,³ Yrene Themistocleous,⁴ Nick J. Edwards,⁴ Sarah E. Silk,^{4,5} Jordan
4 R. Barrett,^{4,5} Graeme J.M. Cowan,¹ Giorgio Napolitani,³ Nicholas J. Savill,¹ Simon J. Draper,^{4,5,6}
5 Angela M. Minassian,^{4,5,6} Wiebke Nahrendorf^{1†} and Philip J. Spence^{1†}

6 ¹Institute of Immunology and Infection Research, University of Edinburgh, UK.

7 ²Instituto de Microbiologia, Universidad San Francisco de Quito, Ecuador.

8 ³Weatherall Institute of Molecular Medicine, University of Oxford, UK.

9 ⁴The Jenner Institute, University of Oxford, UK.

10 ⁵Dept. of Biochemistry and Kavli Institute for Nanoscience Discovery, University of Oxford, UK.

11 ⁶NIHR Oxford Biomedical Research Centre, Oxford, UK.

12 * these authors contributed equally

13 † these authors share senior authorship

14 correspondence: wnahrendorf@ed.ac.uk and pspence@ed.ac.uk

15 Abstract

16 Immunity to severe malaria is acquired quickly, operates independently of pathogen load and
17 represents a highly effective form of disease tolerance. The mechanism that underpins tolerance
18 remains unknown. We developed a human re-challenge model of falciparum malaria in which
19 healthy adult volunteers were infected three times over a 12 month period to track the development
20 of disease tolerance in real-time. We found that parasitemia triggered a hardwired emergency host
21 response that led to systemic inflammation, pyrexia and hallmark symptoms of clinical malaria
22 across the first three infections of life. In contrast, a single infection was sufficient to reprogramme
23 T cell activation and reduce the number and diversity of effector cells upon re-challenge. Crucially,
24 this did not silence stem-like memory cells but instead prevented the generation of cytotoxic
25 effectors associated with autoinflammatory disease. Tolerised hosts were thus able to prevent
26 collateral tissue damage in the absence of anti-parasite immunity.

27 Introduction

28 The epidemiology of human malaria clearly shows that immunity develops in two distinct phases.
29 First, individuals acquire protection against severe life-threatening disease and in areas of high
30 transmission this occurs very quickly (often before 12 months of age)^{1, 2, 3, 4}. Then after many years
31 of exposure protection against clinical malaria is established, which promotes the transition to
32 asymptomatic infection (usually in adolescence)⁵. This temporal dissociation between clinical
33 immunity and immunity to severe malaria suggests that they are underpinned by different
34 mechanisms of host defense. In agreement, clinical immunity often coincides with control of
35 parasitemia (and can therefore be supported by mechanisms of host resistance) whereas immunity
36 to severe malaria is acquired independently of pathogen load and is a form of disease tolerance¹.
37 One leading hypothesis suggests that broadly neutralising antibodies that recognise variant surface
38 antigens associated with severe malaria (such as group A/DC8 PfEMP1) could prevent severe
39 disease without affecting total pathogen load². In this scenario, immunity to severe malaria would
40 depend upon the rapid production of antibodies that can specifically eliminate pathogenic variants.
41 At present, there is limited *in vivo* evidence that such broad cross-reactivity can be achieved or that
42 neutralising antibodies can be produced within the first year of life to inhibit cytoadherence and
43 reduce sequestration^{6, 7}. The mechanism that underpins disease tolerance in human malaria
44 therefore remains unclear.

45 An alternative explanation is that the host response to infection is quickly modified to minimise the
46 harm caused by malaria parasites. It is well known that metabolic adaptations are induced during
47 the blood cycle to increase host fitness^{8, 9, 10} and control of inflammation might provide an additional
48 path towards disease tolerance¹¹. In support of this argument, inflammation decreases with
49 exposure in children (even at high parasite densities)¹² and pathogenic immune responses can be
50 silenced to minimise tissue stress and toxicity in mice¹³. Importantly, host control of inflammation
51 as a defense strategy would not rule out a role for variant surface antigens in severe disease. After
52 all, inflammation, tissue damage and hypoxia could create the right conditions for endothelium
53 activation and the selection of pathogenic variants¹⁴. As such, reducing inflammation may minimise
54 the preferential expansion of parasites associated with severe malaria - this would represent a
55 highly effective route to disease tolerance that would not be influenced by parasite strain or
56 genotype.

57 Controlled human malaria infection (CHMI)¹⁵ offers a unique opportunity to investigate mechanisms
58 of disease tolerance *in vivo*. Healthy malaria-naïve volunteers are inoculated with live (non-
59 attenuated) parasites and their response is tracked throughout infection by repeated sampling (inc.
60 all-important pre-infection samples); volunteers are inoculated with the same clonal malaria parasite
61 (with known variant surface antigen expression) to remove parasite genotype/phenotype as
62 confounding variables; and infections can be terminated at the same parasitemia to maintain a
63 consistent pathogen load. Importantly, this threshold can be safely set at 5,000 - 10,000 parasites
64 ml⁻¹ to challenge the immune system with an enormous antigen load (more than 10⁷ parasites per
65 litre of blood at the peak of infection)¹⁴. What's more, adults have a far higher incidence of severe
66 disease than children during a first-in-life malaria episode, which means we can study the most at
67 risk group of individuals^{16, 17}. We therefore developed a human re-challenge model of falciparum
68 malaria to track the development of disease tolerance in real-time.

69 Results

70 *The risk of severe malaria decreases exponentially with exposure*

71 We first asked how quickly mechanisms of disease tolerance could be established in an area of
72 endemicity. We re-analysed data from a prospective cohort study undertaken in an area of high
73 transmission in Tanzania¹. Here the authors performed longitudinal sampling with active case
74 detection in more than 800 infants and recorded each independent infection (including pathogen
75 load and disease severity) from birth to 4 years of age. Crucially, there was no reduction in pathogen
76 load across the study period as measured by microscopy (circulating parasitemia) or HRP2 ELISA
77 (total parasite biomass). These data emphasise the absence of host resistance mechanisms in early
78 life. Nonetheless, the authors described a rapid decrease in the incidence of severe malaria
79 consistent with acquired immunity. To ask how quickly the risk of severe malaria decreased we
80 performed maximum likelihood estimation to select the best model fit for these data (Extended Data
81 Figure 1). We asked whether the risk of severe malaria remained constant; decreased linearly or
82 exponentially with exposure; or decreased suddenly after n infections (where $n = 1, 2, 3$ etc.). The
83 latter stepwise model performed poorly and was removed from further analysis. In contrast, the
84 linear and exponential models provided a good fit and performed better than a constant risk model.
85 To increase our sample size we repeated this analysis and included cases of moderately severe
86 malaria - we collectively describe these episodes of malaria as complicated as 87.7% led to
87 hospitalisation. Once again, the linear and exponential models provided a good fit with the latter
88 performing better by both log likelihood and AIC. Taken together, our results demonstrate that the
89 risk of severe or complicated malaria is highest during the first infection of life and decreases
90 exponentially thereafter (Figure 1A-B). Mechanisms of disease tolerance are therefore beginning to
91 be established after a single malaria episode.

92 *Developing a human re-challenge model of malaria*

93 To identify host adaptations that could quickly reduce the risk of severe disease we developed a
94 homologous re-challenge model of malaria using the most virulent human parasite *Plasmodium*
95 *falciparum*. Ten healthy malaria-naive adult volunteers were recruited and infected by intravenous
96 injection of parasitised red blood cells during the VAC063A and VAC063B clinical trials; all returned
97 for re-challenge between 4 and 8 months later (during the VAC063B and VAC063C trials,
98 respectively). Six volunteers who took part in both VAC063A and VAC063B were infected for a third
99 time during VAC063C. A blood challenge model was chosen because it standardises the infectious
100 dose, prolongs the period of blood-stage infection (cf mosquito challenge) and removes liver-stage
101 immunity as a possible confounding factor^{18, 19}. Importantly, we used a recently mosquito-
102 transmitted parasite line (< 3 blood cycles from liver egress)²⁰ since mosquitoes have been shown
103 to reset *Plasmodium* virulence²¹. Volunteers attended clinic the day before infection (baseline), every
104 12 hours from the day after infection until diagnosis (the peak of infection) and then during the
105 period of drug treatment, which was initiated within 12 hours of diagnosis. These frequent visits
106 allowed for regular blood sampling to construct a detailed longitudinal time-course of each
107 infection. Remarkably, we found that the parasite multiplication rate (and peak parasitemia) were
108 comparable between the first, second and third malaria episode (Figure 1C and Supplementary
109 Table 1). Furthermore, we found no significant change in symptoms or the frequency or severity of
110 pyrexia, anaemia, lymphopenia or thrombocytopenia (Figure 1D-G). These data thus show that

111 healthy adults do not acquire mechanisms of resistance (to reduce their pathogen load) and remain
112 susceptible to clinical malaria. Our homologous re-challenge model therefore recapitulates the key
113 features of endemic malaria in early life.

114 *Infection triggers a hardwired emergency host response*

115 The absence of anti-parasite immunity means that any change in the host response to infection can
116 not be attributed to a reduced number of circulating parasites. Our model therefore provides the
117 ideal setting in which to investigate mechanisms of disease tolerance. One potential route to
118 tolerance might be to reduce systemic inflammation - this correlates with clinical immunity in
119 endemic regions¹² but whether it also coincides with immunity to severe disease is not known. To
120 capture the acute phase response we used whole blood RNA-sequencing and DESeq2²² to identify
121 differentially expressed genes at diagnosis in first, second and third infection. We found a
122 remarkably similar pattern of interferon-stimulated gene expression regardless of infection number
123 (Extended Data Figure 2A-C). Furthermore, functional gene enrichment analysis showed that the
124 hierarchy of GO terms was near-identical (Figure 2A). These transcriptional signatures were
125 consistent with the rapid recruitment of activated monocytes and neutrophils into peripheral blood,
126 which has been extensively described in naive hosts infected with *P. falciparum*^{23, 24} and *P. vivax*^{25,}
127 ²⁶, but it was surprising to see no obvious change upon re-challenge. Nevertheless, by analysing
128 each infection independently it was possible that we were missing important quantitative
129 differences and so we performed direct pairwise comparisons between first, second and third
130 infection. Initially, we compared each pre-infection time-point to identify season-dependent shifts
131 in baseline gene expression - we found zero differentially expressed genes between infections (adj
132 $p < 0.05$ and absolute fold-change > 1.5). When we then compared each diagnosis time-point to
133 identify adaptations in the host response we again found zero differentially expressed genes (Figure
134 2B); evidently, the first three infections of life trigger a hardwired emergency response that is not
135 influenced by season or previous exposure.

136 Nonetheless, host control of inflammation may not be transcriptionally regulated and so we directly
137 measured systemic inflammation at protein level using a highly multiplexed custom bead assay (39
138 plasma analytes indicative of inflammation, coagulation, oxidative stress and metabolism). By
139 analysing the concentration of each analyte through time we could fit mixed-effects models to test
140 the hypothesis that inflammation was attenuated upon re-challenge (Extended Data Figure 2D).
141 What we actually found, however, was that many of the prototypical products of monocyte and
142 neutrophil activation (such as CXCL10, IL-1RA & MPO) were increased in second and third infection
143 (Figure 2C). The same was true for hallmark cytokines associated with innate lymphoid cell (ILC) or
144 T cell activation (such as IFN γ). Collectively, these data demonstrate that *P. falciparum* triggers a
145 hardwired emergency host response throughout the first three infections of life. And crucially, we
146 find no evidence that systemic inflammation is quickly attenuated.

147 *A single malaria episode attenuates T cell activation*

148 We therefore moved on to examine adaptive T cells, which are inherently plastic, proliferative and
149 long-lived, and uniquely placed to quickly and permanently alter the host response to infection. The
150 acute phase response to malaria causes extreme lymphopenia leading to a 30 - 70% loss of
151 circulating cells at the peak of infection (Figure 1F). The majority of these are recruited to the

152 inflamed spleen^{27, 28} and so it is difficult to assess T cell activation and differentiation at diagnosis.
153 Instead, we need to analyse T cell activation after drug treatment when the emergency response
154 begins to resolve and T cells return to the circulation²⁹. At this time-point, analysing T cell
155 phenotypes in peripheral blood can provide a readout of tissue-specific immune responses. Post-
156 treatment blood samples were not available from the VAC063A or VAC063B clinical trials but were
157 collected during VAC063C. In this trial, we recruited new malaria-naive controls to provide time-
158 matched samples from first infection and infected 11 volunteers contemporaneously (three first
159 infection, two second infection and six third infection) (Supplementary Table 1). As such, we
160 switched to a cross-sectional analysis of VAC063C to incorporate post-treatment time-points.

161 Six days after drug treatment (designated T6) lymphopenia had completely resolved and all other
162 clinical symptoms of malaria (inc. fever) had receded. Furthermore, markers of systemic
163 inflammation had returned almost entirely to baseline and this was observed in every volunteer
164 regardless of infection number (Extended Data Figure 3A). It was therefore a surprise to find a large
165 transcriptional signature in whole blood at T6 (Extended Data Figure 3B). This signature did not
166 overlap with the emergency response captured at diagnosis and instead the differentially expressed
167 genes had unique functional enrichment terms relating to cell cycle and nuclear division (Extended
168 Data Figure 3C). Remarkably, this proliferative burst was only observed in volunteers undergoing
169 their first infection of life (Extended Data Figure 3D).

170 Myeloid cells are generally terminally differentiated and do not proliferate after their release from
171 the bone marrow; it therefore seemed likely that our whole blood RNA-sequencing data were
172 capturing the return of activated T cells to the circulation. To explore this further we sorted CD4⁺ T
173 cells with an effector or effector memory phenotype (CCR7^{neg} CD45RA^{neg}), which have been shown
174 to dominate the adaptive response to malaria in a naive host²⁹. Sorting was performed on whole
175 blood one day before challenge and six days after drug treatment (Supplementary Data File 1).
176 Analysis of the cell surface markers used for sorting revealed dramatic activation of CD4⁺ T cells in
177 first infection but not second or third infection (Figure 3A) and this striking observation was repeated
178 in a separate CHMI study (VAC069) that infected volunteers with *Plasmodium vivax*, a different
179 species of human malaria parasite that is evolutionarily divergent from *P. falciparum*³⁰ (Figure 3B
180 and Extended Data Figure 4A). Our data therefore reveal that the unique feature of a first-in-life
181 malaria episode is fulminant CD4⁺ T cell activation and that this response is attenuated as the risk
182 of severe disease begins to exponentially decrease.

183 *T_H1 polarisation is a unique feature of first infection*

184 To explore the transcriptional landscape of activated CD4⁺ T cells we undertook RNA-sequencing
185 on the sorted effector (effector memory) CD4⁺ T cells obtained from volunteers infected with *P.*
186 *falciparum*. We found almost 6000 differentially expressed genes at T6 in first infection (adj p < 0.05
187 and > 1.5 fold-change) and functional gene enrichment analysis showed that these cells were
188 proliferative and had increased their capacity for oxidative phosphorylation (Figure 3C and
189 Extended Data Figure 4B). Furthermore, they had upregulated each of the major costimulatory and
190 inhibitory receptors required to control their fate, and increased their expression of the signature
191 chemokine receptors and transcription factors associated with T_H1 polarisation. What's more, the
192 cytokines IFN γ and IL-21 were both strongly induced, which could indicate that infection stimulates
193 double-producers³¹ or that follicular helper T cells were also released from the spleen (Figure 3D).

194 In third infection, IFN γ and IL-21 were once again significantly upregulated at T6 together with T_H1-
195 associated chemokine receptors; CD4⁺ T cells are thus transcriptionally responsive to re-challenge
196 (Figure 3C-D). Yet remarkably, the transcription factors that drive T_H1 differentiation (T-bet and
197 STAT1) were no longer induced, and neither were the costimulatory molecules or inhibitory
198 receptors observed in first infection. We therefore asked what modifies CD4⁺ T cell activation to
199 avert T_H1 polarisation upon re-challenge. We found no transcriptional evidence that they were
200 quiescent or anergic in third infection (Extended Data Figure 4C) and crucially the transcription
201 factors that epigenetically enforce exhaustion were not upregulated (Figure 3C). Furthermore, there
202 was no evidence for activation-induced cell death (Extended Data Figure 4D) and TCR β sequencing
203 revealed near-identical repertoires before and after infection, which shows that attenuation was not
204 caused by the clonal deletion of activated T cells after the first or second malaria episode (Figure
205 3E). There was also no evidence that activated CD4⁺ T cells were diverted towards a regulatory
206 fate; for example, hallmarks of T_R1 differentiation (such as Eomes and IL-10) were absent (Figure
207 3C-D).

208 An alternative explanation could be suppression by conventional regulatory CD4⁺ T cells but our
209 data showed that Tregs were activated in first (not third) infection (Extended Data Figure 4E). It
210 therefore appears that malaria-experienced hosts can launch a specialised adaptive T cell
211 programme that maintains cytokine production without causing extensive activation, proliferation
212 or T_H1 polarisation. Importantly, we can identify this modified T cell response by transcriptional
213 profiling of whole blood (Extended Data Figure 4F) and it will therefore be possible to identify
214 tolerised hosts in an endemic setting without the need for complex cell isolation protocols.

215 *Stem-like memory CD4⁺ T cells respond to re-challenge*

216 A major limitation of bulk RNA-sequencing is that there is very little power to detect transcriptional
217 changes if only a small proportion of cells are responding, as seemed to be the case in third
218 infection. The transcriptional landscape of re-activated cells therefore remained largely unclear. To
219 overcome this limitation we used single cell RNA-sequencing to examine individual CD4⁺ T cells,
220 which were sorted at baseline and T6 from three volunteers undergoing first infection and three
221 undergoing third infection; samples were barcoded with oligo-tagged antibodies and superloaded
222 onto the 10X Chromium platform³². Three libraries were then prepared and sequenced (cell surface,
223 5' gene expression and V(D)J) and after quality control (including doublet exclusion) our dataset
224 contained approximately 25,000 cells per infection with a median of 75,000 reads and 1000 genes
225 per cell (Extended Data Figure 5A-B). Initially, we concatenated all data to identify the heterogeneity
226 of CD4⁺ T cells across the dataset and uncovered 13 unique clusters (7 with a non-naive phenotype)
227 (Figure 4A and Extended Data Figure 5C). We then split the data by volunteer and time-point to
228 examine cluster abundance by linear regression and found that in third infection a single cluster of
229 CD4⁺ T cells (cluster 10) had expanded at T6 (Figure 4B). Importantly, this cluster was
230 transcriptionally high for the canonical activation marker CD38 (Extended Data Figure 5D).

231 We therefore examined the signature genes associated with cluster 10 and found enrichment of the
232 transcription factor TCF1 (Supplementary Table 2); this has been associated with circulating T_{FH}
233 cells in a mouse model of malaria³³ but we found no significant enrichment for PD1, CXCR5 or BCL6
234 (Extended Data Figure 5E). Instead, we found that cluster 10 was enriched for LEF1, SELL, TRIB2
235 and PELL1 (Figure 4C), which have all been linked to the maintenance of stem-like properties in T

236 cells^{34, 35, 36}. Indeed, we found that BLIMP1, whose induction is required for terminal differentiation,
237 was repressed in cluster 10 (Extended Data Figure 5F) and BLIMP1 is a known target of TCF1^{37, 38}.
238 Cluster 10 was also found to expand in first infection but was exceeded by cluster 11, which was
239 similarly high for CD38 but otherwise transcriptionally distinct (Figure 4B-C and Extended Data
240 Figure 5D). Cells in cluster 11 were enriched for signature genes associated with T_H1 polarisation,
241 terminal differentiation and cytotoxicity, including NKG7 and KLRB1 (CD161), which are hallmarks
242 of rapidly responding short-lived effector cells^{39, 40}. Notably, cluster 11 downregulated TCF1 and
243 this could also be seen in our bulk RNA-sequencing data (Figure 3C and Extended Data Figure 5F).

244 There was no evidence, however, that cells in cluster 11 were descendants of cluster 10 and instead
245 trajectory analysis indicated bifurcation along the TCF1/BLIMP1 axis (Figure 4D and Extended Data
246 Figure 5G). In agreement, TCR V gene usage in cluster 10 shared remarkable overlap with all other
247 T cell clusters but diverged in cluster 11 (Figure 4E). For example, cells in cluster 11 increased
248 TRAV16 / TRBV18 and minimised TRBV5-1 leading to an overall reduction in repertoire diversity
249 (Figure 4F and Supplementary Data File 2). These data are consistent with the rapid clonal
250 expansion of short-lived effectors in first infection, which are silenced upon re-challenge. In
251 contrast, stem-like memory T cells are re-activated and increase their repertoire diversity (to
252 resemble naive T cells) during third infection (Figure 4F). This suggests that cluster 10 is selected
253 for a polyclonal repertoire across multiple malaria episodes and is consistent with reverse TCR
254 evolution⁴¹. Crucially, the maintenance of stem-like memory appears to support long-lived humoral
255 responses as we observe remarkable stepwise boosting of class-switched IgG antibodies against
256 MSP1 and AMA1 (Figure 4G).

257 *Cytotoxic T cells are silenced for a minimum 8 months*

258 The terminal differentiation of cytotoxic CD4⁺ T cells has been described in autoinflammatory
259 disease, the tumour microenvironment and chronic (or latent) viral infection^{42, 43, 44}. We were
260 nevertheless surprised that our bulk and single cell RNA-sequencing data both suggested that T_H1
261 polarised CD4⁺ T cells acquired transcriptional features of cytotoxicity during a first-in-life malaria
262 episode (Figure 3D and 4C). Furthermore, the scale of activation (up to 80% of all circulating cells
263 with an effector or effector memory phenotype (Figure 3A-B)) was staggering, and far exceeded
264 observations made in other human challenge models of acute infection, such as influenza⁴⁵ or
265 typhoidal salmonella⁴⁶. Our data therefore suggested that rather than the response to re-challenge
266 being unusual, the host response to a first infection was excessive and disproportionate. To explore
267 this idea we used mass cytometry so that we could examine more cells, extend our analysis to all
268 major T cell subsets and quantify the heterogeneity of activated cells at protein level. To this end
269 we designed an antibody panel that prioritised key markers of T cell function and fate
270 (Supplementary Table 3).

271 Whole blood samples were preserved in Cytodelics Stabilisation buffer within 30 minutes of blood
272 draw at baseline, diagnosis and T6 (as well as during convalescence) during VAC063C. As before,
273 we concatenated all data to identify the heterogeneity of T cells across the entire dataset and
274 uncovered 49 unique clusters (Supplementary Data File 3). As expected most of the diversity was
275 observed within the non-naive CD4⁺ and CD8⁺ T cell subsets (Figure 5A). Tracking the frequency of
276 each cluster through time then resolved dynamic changes in the T cell compartment
277 (Supplementary Data File 4) and we performed linear regression on cell count data using edgeR⁴⁷

278 to identify the differentially abundant clusters at each time-point (FDR < 0.05 and absolute fold-
279 change > 2).

280 In first infection eighteen T cell clusters increased in abundance at T6 and all had an activated
281 (CD38^{hi} Bcl2^{lo}) phenotype; these were comprised of twelve adaptive and six innate-like clusters that
282 spanned every T cell lineage (Figure 5B-D). In sum, these clusters accounted for approximately
283 40% of the T cell compartment (Extended Data Figure 6A) and included cytotoxic effectors
284 belonging to the CD8⁺, gamma delta and NK T cell subsets - all were characterised by upregulation
285 of the chemokine receptor CX3CR1 (Figure 5E). CD4⁺ T cells nevertheless dominated this response
286 and we observed enormous heterogeneity with the expansion of nine distinct clusters. There were
287 common traits (such as expression of the memory marker CD45RO) and most had an effector
288 (CCR7^{neg}) phenotype but the expression of other activation and differentiation markers (inc. T-bet)
289 was highly variable (Figure 5E). The largest cluster of activated CD4⁺ T cells had an unusual CD27^{neg}
290 CX3CR1^{pos} cytotoxic phenotype and there were other unexpected features of terminal
291 differentiation such as the appearance of perforin-expressing CD161^{pos} effectors. We therefore
292 used limma to complement our analysis of cluster abundance and modelled changes in marker
293 expression through time; this confirmed significant upregulation of both granzyme B and perforin
294 in CD4⁺ T cells six days after drug treatment (Extended Data Figure 6B). Evidently, cytotoxicity is a
295 cardinal feature of the entire T cell response to a first-in-life malaria episode.

296 In third infection the T cell response was primarily driven by activated innate-like T cells but their
297 abundance was substantially reduced (compared to first infection) and the induction of granzyme
298 B and perforin was suppressed (Figure 5C-D and Extended Data Figure 6B). The number of
299 cytotoxic CD8⁺ T cells was also reduced but the most dramatic change was observed within the
300 CD4⁺ T cell compartment. Here all but one of the nine clusters that expanded in first infection was
301 attenuated and the previously dominant CD27^{neg} CX3CR1^{pos} cytotoxic cluster was completely
302 silenced. These changes were not associated with an increase in regulatory T cells (Foxp3^{hi} CD39^{hi}
303 cells did not expand after re-challenge) or an upregulation of suppressor molecules (Extended Data
304 Figure 6B). In fact, only two clusters increased in size in third compared to first infection - a small
305 subset of double negative T cells and a cluster of T-bet^{lo} Eomes^{neg} effector memory CD4⁺ T cells
306 (Figure 5C and 5E). The majority of activated CD4⁺ T cells belonged to this cluster and in contrast
307 to first infection these cells had already increased in abundance at diagnosis (Supplementary Data
308 File 4); these presumably represent the stem-like memory cells identified by single cell RNA-
309 sequencing. In sum, approximately 10% of the T cell compartment was activated after re-challenge,
310 which more closely aligns with the scale of T cell activation observed in other febrile human
311 infectious diseases.

312 *Controlling T cell activation protects host tissues*

313 Collectively, these data show that the T cell response to a first-in-life malaria episode is dominated
314 by heterogeneous CD4⁺ T cells that present with unusual features of terminal differentiation and
315 cytotoxicity. To directly test whether T cell activation could be pathogenic we measured biomarkers
316 of collateral tissue damage, a common histological feature of severe malaria. The blood-stage of
317 infection frequently causes liver injury in naive hosts^{48, 49, 50} and auto-aggressive T cells can directly
318 kill primary human hepatocytes⁵¹ - we therefore measured alanine aminotransferase (ALT) to
319 provide a readout of hepatocellular death *in vivo*. In first infection, two out of three volunteers had

320 abnormal ALT (more than the upper limit of the reference range) when activated T cells were
321 released from inflamed tissues (Extended Data Figure 7A). This was accompanied by increased
322 gamma-glutamyl transferase (GGT) and aspartate aminotransferase (AST) leading to moderate or
323 severe adverse events in both volunteers. In contrast, there was little evidence of any deviation from
324 baseline in liver function tests after re-challenge. To expand our sample size, we performed a meta-
325 analysis using a previously published surrogate dataset; specifically, we examined post-treatment
326 ALT measurements in almost 100 volunteers experiencing a first-in-life infection as part of a human
327 challenge study⁴⁹. Importantly, we only included CHMI trials that were directly comparable to our
328 own re-challenge study - that is they used the same clonal parasite genotype (3D7 or the parental
329 NF54 line); parasites had recently been mosquito transmitted; and similar end-points were applied
330 (treatment at around 10,000 parasites ml⁻¹) (Figure 6A). Remarkably, we found that the prevalence
331 of abnormal ALT was reduced from 75% during first infection to 25% upon re-challenge (Figure
332 6B). And in those rare cases where ALT was increased in second or third infection adverse events
333 were mild (not moderate or severe) even though pathogen load was increased.

334 We then looked more closely at the relationship between T cell activation and liver injury in our
335 cohort. We found a strong positive correlation between ALT and the frequency of activated effector
336 or effector memory CD4⁺ T cells, regulatory T cells and cytotoxic T cells (Figure 6C and
337 Supplementary Table 4). Of note, these all had a strong negative correlation with antibody titres.
338 What's more, they had no discernible relationship with markers of systemic inflammation or clinical
339 symptoms of malaria, which were instead closely associated with each other but located in a
340 separate clade. Finally, we co-cultured PBMC from first infection with HepG2 cells (an immortalised
341 hepatocyte cell line) and could show enhanced killing at T6 (compared to baseline) *in vitro* (Figure
342 6D and Extended Data Figure 7B-C). This was particularly prominent for v315 who had by far the
343 largest population of activated CD27^{neg} CX3CR1^{pos} cytotoxic CD4⁺ T cells (Extended Data Figure
344 6A). Taken together, these data show that the risk of tissue damage and injury can be significantly
345 reduced in the absence of parasite control, which provides the first *in vivo* evidence that long-lived
346 mechanisms of disease tolerance operate in human malaria and can be acquired after a single
347 infection. Moreover, protection does not require the attenuation of systemic inflammation but
348 instead coincides with host control of T cell activation and cytotoxicity.

349 Discussion

350 It has long been recognised that immunity to severe malaria is acquired early in life, offers protection
351 against all manifestations of severe disease and usually precedes clinical immunity (the transition
352 to asymptomatic infection) by more than a decade^{2, 3, 4, 5}. We also know that immunity to severe
353 malaria does not require improved parasite control and is thus underpinned by acquired
354 mechanisms of disease tolerance¹. This is an important distinction to make if we want to understand
355 how to reduce malaria mortality. Host control of inflammation could provide a rapid route to disease
356 tolerance but our data show that malaria parasites trigger a hardwired emergency response across
357 the first three infections of life. This correlates closely with symptomatology in our cohort and is
358 consistent with repeated episodes of fever in children living in endemic settings. In contrast, T cell
359 activation is quickly modified to limit the number and diversity of effector cells, and to avoid cell
360 fates associated with collateral tissue damage and autoinflammatory disease. Our data can
361 therefore begin to explain why large multi-centre genome-wide association studies have repeatedly
362 failed to identify immune loci that associate with severe malaria⁵² - variation in human T cells is
363 almost exclusively driven by non-heritable factors⁵³.

364 If we want to understand how the immune response contributes to severe disease we instead need
365 to ask how malaria triggers such widespread and indiscriminate activation of cytotoxic T cells.
366 These are enriched for markers of terminal differentiation and likely represent short-lived effectors
367 (as evidenced by the downregulation of TCF1 and de-repression of BLIMP1 in CD4⁺ T cells). What
368 remains unclear, however, is whether these are malaria-specific cells or activated via bystander
369 (TCR-independent) mechanisms. If the latter, these could be derived from pre-existing memory
370 cells, which have a far lower threshold for activation than naive cells^{54, 55}. This would certainly explain
371 the magnitude of the response, and may also explain the increased susceptibility of adults to severe
372 disease during a first-in-life infection (adults have a larger memory pool than infants and children).
373 Alternatively, malaria may activate autoreactive T cells in the same way that it can activate B cells
374 that produce autoantibodies^{56, 57}. Central tolerance (which deletes self-reactive clones in the
375 thymus) is only partially effective and there is enormous degeneracy in TCR reactivity⁵⁸. Systemic
376 infection with a pathogen carrying more than 5000 protein-coding genes may therefore lead to
377 considerable cross-reactivity between parasite and host. In either case, the activation of bystander
378 or cross-reactive T cells would explain our observation that the TCR β repertoire is essentially
379 unchanged after a first malaria episode.

380 So how would activation of a large heterogeneous pool of T cells promote severe disease? One
381 possibility is that T cell activation causes extensive activation of the endothelium leading to
382 enhanced parasite cytoadherence and increased pathogen load (an important contributing factor
383 for severe malaria). This has yet to be formally tested but could be assessed *ex vivo* using 3D
384 models of the human microvasculature⁵⁹. This is an important next step because group A/DC8
385 variants are known to associate with severe disease but do not have an intrinsic growth advantage
386 *in vivo*¹⁴; a host factor must therefore promote their selection. An alternative (though not mutually
387 exclusive) explanation is that cytotoxic T cells disrupt the endothelial barrier in critical organs and
388 there is emerging evidence for this pathological process in children and adults with cerebral
389 malaria^{60, 61}. Furthermore, cytotoxicity may damage parenchymal tissue and our data support a
390 direct role for activated T cells in hepatocyte death. Remarkably, we found that PBMC-mediated
391 killing of HepG2 cells *in vitro* did not require peptide loading and we therefore propose that tissue

392 damage is the result of TCR-independent off-target cytotoxicity. This would explain why we only
393 observe raised transaminases after parasite clearance - activated T cells traffic to the liver during
394 resolution of the immune response to facilitate their clearance⁶². In this scenario, liver injury would
395 be attenuated after re-challenge because the size of the T cell response is diminished. This could
396 be tested *in vivo* using fine needle liver aspirates, which have recently been obtained during CHMI
397 to examine tissue resident memory⁶³. In the meantime, we can conclude that explosive cytotoxic T
398 cell activation and tissue damage are the unique features of a first-in-life infection and both are
399 silenced after a single malaria episode to promote tissue health. Importantly, this host adaptation
400 persists for at least 8 months, which would be sufficient to maintain immunity against severe malaria
401 through a prolonged dry season.

402 It is therefore apparent that we need to start asking how the T cell response to malaria is modified
403 so quickly if we want to obtain a mechanistic understanding of disease tolerance. One possibility is
404 that infection initiates heritable epigenetic programmes that reduce T cell responsiveness. Our data
405 do not provide transcriptional evidence of anergy or exhaustion but this hypothesis needs to be
406 directly tested. An alternative explanation could be suppression by conventional (thymus-derived)
407 regulatory T cells but we found no evidence for their activation in second or third infection - it seems
408 that Tregs are redundant at this point because there is no explosive effector response to keep in
409 check. In much the same way, we found no evidence for the development of IL-10 producing T_R1
410 cells, which have been extensively described in endemic settings^{64, 65, 66}. At first glance, it could be
411 assumed that this is because T_R1 cells are generated in the context of chronic stimulation and CHMI
412 is a model of acute infection. However, even in CHMI (where drug treatment is usually initiated
413 within 8 to 12 days of infection) malaria chronically stimulates the immune system. This is because
414 once-infected red cells carry parasite-derived surface antigens and continue to circulate for weeks
415 after drug treatment⁶⁷; follicular dendritic cells present antigens within follicles for months (possibly
416 years)⁶⁸; and hemozoin (an insoluble by-product of infection) persists in lymphoid tissues
417 indefinitely⁶⁹. Indeed, evidence of chronic stimulation can clearly be seen in our study - two clusters
418 of activated (CD38^{hi} Bcl2^{lo}) gamma delta T cells are still expanded 45 days after infection
419 (Supplementary Data File 4). It is this persistence of parasite-derived material that we believe is
420 responsible for the long-term protection afforded by a single malaria episode. After all, hemozoin-
421 loaded dendritic cells have a reduced capacity to stimulate T cell proliferation *in vitro*⁷⁰ and a similar
422 mechanism operating within the spleen could provide the simplest explanation for tolerance.

423 In much the same way, antigen presenting cells can be modified by chronic viral infection and this
424 has been shown to preferentially promote the generation of memory CD8⁺ T cells with stem-like
425 properties⁷¹. A similar stem-like fate has recently been described for CD4⁺ T cells⁷² and these appear
426 to share remarkable overlap with the TCF1⁺ cluster that is re-activated in our cohort upon re-
427 challenge. TCF1 endows memory CD4⁺ T cells with the capacity for asymmetric division⁷³ to
428 promote self-renewal and the differentiation of T_{FH} precursors^{37, 74}, which are primed to enter
429 germinal centres or else support B cell responses in the extra follicular pathway. Crucially,
430 asymmetric division is the most efficient way to generate long-lived immunity and the activation of
431 stem-like memory CD4⁺ T cells in third infection (8 months after second infection) coincides with
432 the boosting (MSP-1) and diversification (AMA-1) of parasite-specific class-switched antibodies. A
433 second requirement for long-lived immunity when pathogens persist is reverse TCR evolution,
434 which gradually selects for low affinity T cell clones; this is beneficial because memory cells with a
435 high affinity TCR are driven towards senescence by chronic stimulation⁴¹. Importantly, effective anti-

436 parasite immunity (and the transition to asymptomatic infection) does not require high affinity
437 antibodies but instead antibody diversification^{75, 76, 77}. The polyclonal repertoire of stem-like memory
438 CD4⁺ T cells in third infection may therefore represent the selection of low affinity clones with
439 increased longevity and an enhanced capacity to support a broad repertoire of B cells. As such, we
440 argue that the slow acquisition of anti-parasite immunity in endemic settings (and in our own CHMI
441 study) is not a failure of T cell help.

442 So do equivalent data from endemic settings support our findings? An important caveat here is that
443 in almost every case samples are collected around the time of drug treatment when activated T
444 cells are still sequestered in inflamed tissues. Nevertheless, we can ascertain that circulating
445 cytotoxic (granzyme B^{pos}) CD4⁺ T cells do not expand in children or adults during an uncomplicated
446 episode of febrile disease⁷⁸. In this study, all of these patients would be expected to have acquired
447 immunity to severe malaria because they have lived for at least 2 years in a perennial high
448 transmission setting (183 infective bites per person per year). We can therefore conclude that there
449 is no evidence of cytotoxicity when the risk of severe disease is low. On the other hand, adults with
450 effective anti-parasite immunity have an expanded population of CD161^{pos} central memory CD4⁺ T
451 cells⁷⁹, which may share some similarities with the stem-like memory cells identified here. That's
452 because stem-like, T_{CM} and T_{FH} cells are all situated on the same branch of the TCF1-BLIMP1 axis
453 (with cytotoxic, T_{H1} and T_{R1} cells on the other side)^{37, 38, 74, 80}. And crucially, the frequency of CD161^{pos}
454 T_{CM} CD4⁺ T cells correlates with naturally acquired antibody titres against a broad range of targets
455 (including RH5). These data are therefore consistent with our findings that exposure to malaria
456 quickly silences pathogenic T cells but does not prevent the maintenance of stem-like memory.
457 That this can be achieved through CHMI (a short drug-cured infection) means that interventions
458 that reduce pathogen load but don't completely eliminate blood-stage parasites could reduce the
459 incidence of clinical malaria in the short-term and have the added benefit of providing long-lived
460 immunity to severe malaria. Moreover, our data indicate that this protection would persist even if
461 these interventions were stopped (drug cover or monoclonal antibodies) or lose efficacy (blood-
462 stage vaccines).

463 Methods

464 *Modelling the risk of severe malaria*

465 To examine the risk of severe disease as a function of prior exposure we used data from a Tanzanian
466 birth cohort¹. In brief, the authors examined 882 children for *P. falciparum* every 2 - 4 weeks and
467 recorded parasite density and disease severity for each independent infection. Data showing the
468 incidence of severe or complicated malaria (the latter summing severe and moderately severe
469 cases) were extracted from Figure 2C and Supplementary Figure 3, respectively, as shown in the
470 published article. We then used these data to plot the total number of cases of malaria (including
471 mild or uncomplicated episodes); impute missing values by least squares regression (as shown in
472 Extended Data Figure 1); and model risk (as a function of exposure) using the fraction of severe or
473 complicated cases divided by the total number of cases at each order of infection. Binomial
474 regression models were then fit using maximum likelihood methods to test whether the empirical
475 data was best explained by a constant risk (no change), a linear decrease in risk or an exponential
476 decay with increasing exposure. To compare model performance we used the Akaike Information
477 Criterion (AIC) to balance goodness of fit with model complexity, and viewed a reduction in $AIC >$
478 2 as indicating a superior model. Maximum likelihood coefficients were estimated
479 with `stats4::mle()` and `stats::glm()`.

480 *Clinical trial design - Plasmodium falciparum*

481 All volunteers were healthy malaria-naive adults aged between 18 and 50 years and were enrolled in
482 up to three CHMI studies - VAC063A (November 2017), VAC063B (March 2018) and VAC063C
483 (November 2018). The VAC063A and VAC063B trials evaluated vaccine efficacy of the recombinant
484 blood-stage malaria protein RH5.1 in AS01_B adjuvant (GSK) whereas the VAC063C trial investigated
485 the durability of anti-parasite immunity. We collected whole blood samples in each trial from the
486 non-vaccinated (control) volunteers and analysed 8 volunteers in VAC063A (all receiving their first
487 infection), 10 volunteers in VAC063B (8 receiving their second infection and 2 their first infection)
488 and 11 volunteers in VAC063C (6 receiving their third infection, 2 receiving their second infection
489 and 3 their first infection). Our study design and laboratory analysis plan are shown in
490 Supplementary Table 1. All clinical trials received ethical approval from the UK NHS Research Ethics
491 Service - Oxfordshire Research Ethics Committee A for VAC063A and VAC063B (reference
492 16/SC/0345) and South Central Oxford A for VAC063C (reference 18/SC/0521) - and were
493 registered at ClinicalTrials.gov (NCT02927145 and NCT03906474). VAC063A-C were sponsored by
494 the University of Oxford, carried out in the UK at the Centre for Vaccinology and Tropical Medicine
495 and conducted according to the principles of the current revision of the Declaration of Helsinki 2008
496 (in full conformity with the ICH Guidelines for Good Clinical Practice). Volunteers signed written
497 consent forms and consent was checked prior to each CHMI. Details of volunteer recruitment,
498 inclusion/exclusion criteria and group allocation can be found in Minassian *et al.* (for VAC063A and
499 VAC063B)⁸¹ and Salkeld *et al.* (for VAC063C)⁸².

500 During each CHMI all volunteers were infected with *P. falciparum* (clone 3D7) blood-stage parasites
501 by direct intravenous infusion. The inoculum was thawed and prepared under aseptic conditions
502 and volunteers received between 452 and 857 infected red cells in a total volume of 5 ml saline.
503 Starting one day after challenge volunteers attended clinic every 12 hours for assessment and blood

504 sampling, and parasite density was measured in real-time by qPCR. The parasite multiplication rate
505 was then calculated by fitting linear models to log₁₀ transformed qPCR data, as previously
506 described⁸³. In VAC063A thick blood films were evaluated at each time-point by experienced
507 microscopists and diagnosis required volunteers fulfil two out of three criteria: a positive thick blood
508 film (one viable parasite in 200 fields) and/or qPCR data showing at least 500 parasites ml⁻¹ blood
509 and/or symptoms consistent with malaria. In VAC063B and C microscopy was dropped to minimise
510 the variation in parasitemia that was observed between volunteers at diagnosis; importantly, this
511 protocol change did not impact volunteer safety and the average parasitemia at diagnosis remained
512 comparable to VAC063A. The new criteria for diagnosis were: asymptomatic with any qPCR result
513 above 10,000 parasites ml⁻¹ or symptomatic with a qPCR result above 5000 parasites ml⁻¹. In all
514 cases, volunteers were treated with artemether and lumefantrine (Riamet) except where its use was
515 contraindicated and atovaquone and proguanil (Malarone) were given instead. In our analysis, we
516 refer to the blood sample taken immediately before drug treatment (< 30 minutes) as the diagnosis
517 time-point.

518 Clinical symptoms of malaria (malaise, fatigue, headache, arthralgia, back pain, myalgia, chills,
519 rigor, sweats, nausea, vomiting and diarrhoea) were recorded by volunteers on diary cards or during
520 clinic visits. All symptoms were recorded as adverse events and assigned a severity score: 0
521 (absent), 1 (transient or mild discomfort), 2 (mild to moderate limitation in activity) or 3 (severe
522 limitation in activity requiring assistance). Pyrexia was scored as absent ($\leq 37.5^{\circ}\text{C}$), mild ($37.6 -$
523 38.2°C), moderate ($38.3 - 38.9^{\circ}\text{C}$) or severe ($\geq 39^{\circ}\text{C}$). And full blood counts and blood chemistry
524 (inc. electrolytes, urea, creatinine, bilirubin, alanine aminotransferase, alkaline phosphatase and
525 albumin) were evaluated at the Churchill and John Radcliffe Hospital in Oxford.

526 *Clinical trial design - Plasmodium vivax*

527 In VAC069A six healthy malaria-naive adults were enrolled to test the infectivity of a new
528 cryopreserved stabilate containing a clonal field isolate of *P. vivax* (PvW1), which had been carefully
529 prepared for use in CHMI⁸⁴. Volunteers were infected with blood-stage parasites by direct
530 intravenous infusion (as above) and the immune response to PvW1 was comprehensively
531 characterised and compared to *P. falciparum* (3D7). In VAC069B three of these volunteers returned
532 for a homologous re-challenge (8-months after VAC069A) and two additional malaria-naive adults
533 received their first challenge with PvW1. In both clinical trials treatment was initiated once two
534 diagnostic criteria were met: a positive thick blood smear, more than 5000 or 10,000 parasites ml⁻¹
535 blood and/or symptoms consistent with malaria. Treatment consisted of artemether and
536 lumefantrine (Riamet) or atovaquone and proguanil (Malarone) if Riamet was contraindicated. Whole
537 blood sampling, processing and downstream analyses were performed analogously to the VAC063
538 trials (see below). VAC069A and B were sponsored by the University of Oxford, received
539 ethical approval from the UK NHS Research Ethics Service - South Central Hampshire A (reference
540 18/SC/0577) - and were registered at ClinicalTrials.gov (NCT03797989). The trials were conducted
541 in line with the current version of the Declaration of Helsinki 2008 and conformed with the
542 ICH Guidelines for Good Clinical Practice.

543 *Processing whole blood for RNA and plasma*

544 Venous blood was drawn into K₂EDTA-coated vacutainers (BD #367835). To preserve RNA for
545 transcriptional analysis 1 ml whole blood was mixed thoroughly with 2 ml Tempus reagent
546 (ThermoFisher #4342792) and samples were stored at -80°C. No more than 2 hours passed
547 between blood draw and RNA preservation. To obtain platelet-depleted plasma 3 ml whole blood
548 was divided into two 2 ml Eppendorf tubes and centrifuged at 1000 xg for 10 minutes (at 4°C) to
549 pellet cellular components. Working on ice, plasma was then carefully transferred to a new 2 ml
550 tube and centrifuged at 2000 xg for 15 minutes (at 4°C) to pellet platelets. Cell-free platelet-depleted
551 plasma was aliquoted into 1.5 ml Eppendorf tubes, snap frozen on dry ice and stored at -80°C.

552 *Whole blood RNA-sequencing*

553 RNA was extracted from whole blood using the Tempus spin RNA isolation reagent kit
554 (ThermoFisher #4380204) according to the manufacturer's instructions. To account for the reduced
555 starting volume and to maintain Tempus stabilizing reagent at the correct final concentration we
556 added just 1 ml PBS to each sample after thawing. Diluted samples were then centrifuged at 3000
557 xg for 30 minutes (at 4°C) to pellet nucleic acids. Pellets were resuspended in RNA purification
558 resuspension solution and centrifuged on a silica column to remove non-nucleic acid contaminants.
559 After washing, the column was incubated for 2 minutes at 70°C before eluting nucleic acids. 40 µl
560 eluate was then subjected to DNA digestion using the RNA clean and concentrator-5 kit (Zymo
561 Research #R1013). Purified RNA was eluted using 30 µl DNase/RNase-free water, quantified using
562 a Qubit Fluorometer (HS RNA assay kit, ThermoFisher #Q32852) and RNA integrity assessed using
563 an Agilent Bioanalyzer 2100 (RNA 6000 nano kit, Agilent #5067-1511). The average RNA integrity
564 number (RIN) was 9 (98% of samples > 8, lowest RIN 7). Libraries were prepared by Edinburgh
565 Genomics (United Kingdom) using the TruSeq stranded mRNA library prep kit (Illumina #20020595).
566 Stranded library preparation allows transcript expression to be estimated more accurately; in
567 particular it is more effective in quantifying anti-sense gene expression, properly assigning
568 transcripts to putative coding genes and to resolve ambiguity in reads from overlapping genes.
569 Libraries were sequenced using the NovaSeq 6000 Illumina platform yielding 50 bp paired end (PE)
570 reads. These short reads are sufficient to accurately capture gene expression thanks to the well
571 annotated human transcriptome. The average number of reads per sample passing QC across all
572 samples was 8.45×10^7 .

573 *Data analysis of whole blood RNA-sequencing*

574 Quality and content of FASTQ files, which contain raw PE sequencing reads, were assessed using
575 FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>). A single sample (volunteer
576 1040 baseline second infection) failed quality control and we therefore excluded all RNAseq data
577 from this volunteer's second infection during analysis. TruSeq primer sequences were removed
578 using Cutadapt v1.9, reads were aligned to the Ensembl release 96 Homo sapiens transcript set
579 with Bowtie2⁸⁵ v2.2.7 (parameters —very-sensitive -p 30 —no-mixed —no-discordant —no-unal)
580 and reads that mapped to globin transcripts were discarded (on average 11.7% of mapped reads,
581 range 1.6 - 38.1%). We opted for bioinformatic globin depletion as it is highly sensitive and
582 reproducible whereas depleting globin during RNA preparation can compromise the amount and
583 quality of RNA recovered^{86, 87}. Following these steps, the average alignment rate to the human

584 transcriptome across all samples was 88%. A matrix of normalised counts for each transcript was
585 obtained from sorted, indexed BAM files using Samtools idxstats
586 (<http://www.htslib.org/doc/samtools.html>). Transcript counts were imported into the
587 R/Bioconductor environment (v3.6) and differential gene expression analyses (pairwise group
588 comparisons) were performed using functions within the DESeq2²² package. lfcShrink was applied
589 to the output of each pairwise comparison (type normal) and lists of differentially expressed
590 transcripts were subsequently analysed in R. Non-coding transcripts were removed and multiple
591 transcripts annotated to the same gene were consolidated by keeping the transcript with the
592 highest absolute fold-change. Only protein-coding transcripts with an adjusted p value (adj p) <
593 0.05 and a fold-change > 1.5 were considered differentially expressed. Volcano/radar/dot plots and
594 heatmaps were generated using the ggplot2⁸⁸ package. The gene lists used for cell cycle analysis
595 were manually compiled from published datasets^{89, 90} and we allocated genes to a single phase
596 based on cell cycle transcriptional network analysis^{91, 92}.

597 *Functional gene enrichment analysis using ClueGO*

598 Lists of differentially expressed genes were imported into ClueGO^{93, 94} v2.5.7. ClueGO identified
599 significantly enriched GO terms (Biological Process and Molecular Function) associated with these
600 genes and placed them into a functionally organised non-redundant gene ontology network based
601 on the following parameters: adj p cutoff = 0.01; correction method used = Bonferroni step down;
602 min. GO level = 5; max. GO level = 11; number of genes = 3; min. percentage = 5; GO fusion = true;
603 sharing group percentage = 40; merge redundant groups with > 40% overlap; kappa score
604 threshold = 0.4; and evidence codes used [All]. Each of the functional groups was assigned a unique
605 colour and a network was then generated using an edge-weighted spring-embedded layout based
606 on kappa score - groups were named by the leading GO term (lowest adj p with min. GO level 5 or
607 6). Merged networks were constructed by inputting two lists of differentially expressed genes; for
608 each GO term information on what fraction of associated genes were derived from each list was
609 retained. Any GO term containing > 60% associated genes from a single list was considered to be
610 enriched in that group, otherwise GO terms were considered to be shared.

611 *Multiplexed plasma protein analysis*

612 The concentration of 39 analytes was measured in plasma samples collected at baseline, during
613 infection, diagnosis, 6 days after drug treatment (T6) and 28 or 45 days post-challenge
614 (convalescence). Plasma was thawed on ice and centrifuged at 1000 xg for 1 minute (at 4°C) to
615 remove potential protein aggregates. We customised 4 LEGENDplex panels from BioLegend and
616 performed each assay on filter plates according to the manufacturer's instructions. Samples and
617 standards were acquired on an LSRFortessa flow cytometer (BD) and FCS files were processed
618 using LEGENDplex software (version 7.1), which automatically interpolates a standard curve using
619 the plate-specific standards and calculates analyte concentrations for each sample. All samples
620 from v1040 were excluded after failing QC and downstream data analysis was performed in R (v3.6).
621 To determine which plasma proteins varied significantly through time we used the lme4 package to
622 fit a separate linear mixed-effects model for each analyte. All available time-points were included
623 and models were fit to log₂ transformed data with time-point as a categorical fixed effect and
624 volunteer as a random effect. A Kenward-Roger approximation was used to calculate p values
625 (using the pbkrtest package), which were adjusted for multiple testing using the Benjamini-

626 Hochberg method. Results were visualised with ggplot2 and analytes with at least a 1.5 fold-change
627 from baseline to diagnosis or T6 are shown. To determine which plasma proteins varied between
628 first infection and re-challenge we used lme4 to fit mixed-effects models that included time-point
629 and infection number as categorical fixed effects (with volunteer as a random effect). In this case,
630 linear hypothesis testing was performed using multcomp's glht function (with Benjamini-Hochberg
631 correction for multiple testing). Only analytes that were significant in both second and third infection
632 (versus first infection) are shown (adj p < 0.05 and fold-change > 1.5).

633 *Flow-sorting CD4⁺ T cell subsets*

634 We flow-sorted CD4⁺ T cell subsets for bulk RNA-sequencing from 3 ml whole blood collected in
635 K₂EDTA vacutainers. After red cell lysis (erythrocyte lysis buffer, eBioscience #00-4300-54)
636 leukocytes were washed in PBS supplemented with 2% fetal bovine serum (heat inactivated and
637 0.22 µm filtered FBS Premium Plus, Gibco #16000044) containing 5 mM EDTA (Life Technologies
638 #AM9260G). We then blocked Fc receptors (human TruStain FcX, BioLegend #422302) and
639 incubated leukocytes for 20 minutes (at 4°C) with the following fluorophore-conjugated antibodies:
640 CD3 (clone OKT3), CD4 (clone OKT4), CD127 (clone A019D5), CD25 (clone M-A251), CCR7 (clone
641 G043H7), CD45RA (clone HI100), CD38 (clone HIT2) and HLA-DR (clone L243) (all from BioLegend).
642 Cells were washed with cold PBS (containing 2% FBS and 5 mM EDTA) and filtered through a 40
643 µm cell strainer (BD #352340) immediately before sorting. We used a FACS Aria III or Fusion cell
644 sorter with a 70 µm nozzle running FACS Diva v8 software (sort setting = purity) to simultaneously
645 sort 10,000 naive (CD127^{pos} CCR7^{pos} CD45RA^{pos}), regulatory (CD25^{hi} CD127^{neg}) and effector or
646 effector memory (CD127^{pos} CCR7^{neg} CD45RA^{neg}) CD4⁺ T cell subsets. Cells were sorted directly into
647 RNase-free sterile 1.5 ml screw cap tubes (ThermoFisher #11529924) containing 1 ml TRIzol
648 Reagent (ThermoFisher #15596026), and incubated for 5 minutes at room temperature. Samples
649 were then stored at -80°C. Note that sort purity was > 95% for every sample - this was assessed
650 in real-time by simultaneously sorting naive CD4⁺ T cells into cold PBS (containing 2% FBS and 5
651 mM EDTA) and re-acquiring these on the cell sorter.

652 *Bulk RNA-sequencing of CD4⁺ T cell subsets*

653 RNA was extracted using a modified phenol-chloroform protocol⁹⁵ with 1-Bromo-3-
654 chloropropane (Sigma-Aldrich #B62404) and Isopropanol (Acros Organics #423835000). Total RNA
655 was quantified and integrity assessed using an Agilent Bioanalyzer 2100 (RNA 6000 pico chip,
656 Agilent #5067-1513); all sequenced samples had a RIN value above 8. cDNA was generated from
657 1 ng total RNA using the SMART-Seq v4 ultra low input RNA kit (Takara Bio #634894) and amplified
658 using 12 cycles of PCR. Amplified cDNA was purified using AMPure XP beads (Beckman Coulter
659 #A63880) and quantified on a Qubit Fluorometer (dsDNA high sensitivity kit, ThermoFisher
660 #Q32851). The quality of the amplified cDNA was then assessed by Bioanalyzer (DNA high
661 sensitivity kit, Agilent #5067-4626). Libraries were constructed from 150 pg cDNA using the Nextera
662 XT DNA library preparation kit (Illumina #FC-131-1024) according to the manufacturer's
663 instructions. As above, libraries were quantified by Qubit and quality was assessed by Bioanalyzer
664 to measure the fragment size distribution. Using this information, samples were combined to create
665 equimolar library pools that were sequenced on a NextSeq 550 Illumina platform to yield 75 bp PE
666 reads; the average number of PE reads per sample passing QC across all samples was 2.74 x 10⁷.

667 *RNA-sequencing analysis of CD4⁺ T cell subsets*

668 Quality and content of FASTQ files were assessed using FastQC and reads were aligned to the
669 Ensembl release 96 Homo sapiens transcript set with Bowtie2 v2.2.7 (parameters `—very-sensitive`
670 `-p 30 —no-mixed —no-discordant —no-unal`). Our median alignment rate was 66.4%
671 after removing primer and adapter traces (SMART-Seq v4 primers, polyG, polyT and polyN) with
672 Cutadapt v1.9. The sorted, indexed BAM files were then used to obtain a matrix of normalised
673 counts for each transcript using Samtools idxstats. Transcript counts were imported into the
674 R/Bioconductor environment (v3.6) and differential gene expression analyses (pairwise group
675 comparisons) were performed using functions within the DESeq2 package. lfcShrink was applied
676 to the output of each pairwise comparison (type normal) and lists of differentially expressed
677 transcripts were filtered by removing all non-coding transcripts and retaining only those with an adj
678 $p < 0.05$ and fold-change > 1.5 . Multiple transcripts annotated to the same gene were consolidated
679 by keeping the transcript with the highest absolute fold-change. Heatmaps and circular stacked
680 bar plots were generated using the ggplot2 package.

681 *Cryopreservation of peripheral blood mononuclear cells*

682 Peripheral blood mononuclear cells (PBMC) were isolated from 5 ml whole blood, which was diluted
683 with an equal volume of Dulbecco's phosphate buffered saline (D-PBS) containing 2% fetal bovine
684 serum (FBS) (STEMCELL Technologies #07905) and layered onto 3.5 ml Lymphoprep in a 15 ml
685 SepMate tube (STEMCELL Technologies #07851 and #07905). SepMate tubes were centrifuged at
686 1200 xg for 10 minutes (at room temperature), the upper plasma-containing layer was discarded
687 and the remaining supernatant above the insert (which contains the PBMC) was poured into a 15
688 ml tube. Cells were then washed twice in D-PBS containing 2% FBS and cell concentration was
689 determined using a CASY cell counter. Finally, PBMC were resuspended in FBS (heat inactivated
690 and 0.22 μm filtered FBS Premium Plus, Gibco #16000044) containing 10% Dimethyl sulfoxide
691 (DMSO, Sigma-Aldrich #D8418) at a concentration of 5×10^6 cells ml^{-1} and transferred to cryovials.
692 These were placed in a Corning CoolCell freezing container, which was subsequently placed at -
693 80°C. After 24 hours, PBMC-containing cryovials were transferred to liquid nitrogen where they
694 were stored long-term. To prepare cryopreserved PBMC for use in experiments cryovials were
695 quickly thawed in a 37°C water bath and diluted by adding 10x volume thawing media (RPMI 1640
696 supplemented with 10% FBS and 20 units ml^{-1} DNase I (Sigma-Aldrich #D4513)) one drop at a time
697 with continuous agitation. Cells were centrifuged at 350 xg for 10 minutes (at room temperature)
698 and washed twice in thawing media. After washing, viable cell counts were calculated using a
699 hemocytometer.

700 *T cell receptor repertoire sequencing*

701 We analysed the TCR β repertoire of the six volunteers who underwent third infection during
702 VAC063C, assessing their bulk repertoire prior to challenge (baseline) and 28 days post-challenge
703 (convalescence) during their first (VAC063A) and second (VAC063B) malaria episode. RNA was
704 extracted from thawed PBMC using the Quick-RNA miniprep plus kit (Zymogen) as per the
705 manufacturer's instructions, including DNase treatment. A modified protocol from Mamedov *et al.*⁹⁶
706 was then used to synthesise cDNA, which was treated with 1 μl Uracyl DNA glycosylase (5 units μl
707 $^{-1}$). A nested PCR then generated TCR β V region amplicons with outer primers using indexed forward

708 primers composed of the SMART synthesis oligo sequence fused to a P7 Illumina tag
709 (CAAGCAGAAGACGGCATAACGAGATXXXXXXXXGGCGAAGCAGTGGTATCAACGCAGAGT) and a
710 reverse primer within the TCR C region fused to a P5 Illumina tag
711 (AATGATACGGCGACACCGAGATCTACACACACSTTKTTCAGGTCCTC). Library QC was
712 performed by Nanodrop and Bioanalyzer, and asymmetric 400 bp + 100 bp sequencing was then
713 performed on an Illumina NovaSeq using custom read primers (ACTCTGCGTTGATACCACTG index
714 with CGAGATCTACACACACSTTKTTCAGGTCCTC for read 1 and
715 GGCGAAGCAGTGGTATCAACGCAGAGT for read 2). The average number of functional TRBV
716 reads was 2.58×10^6 per sample resulting in an average of 13,410 unique CDR3 sequences per
717 sample. Quality control was performed on the raw FASTQ files using FastQC and sequencing data
718 that incorporated UMI was demultiplexed using MiGEC⁹⁷. All sequences were aligned using
719 MiXCR⁹⁸ software utilising IMGT⁹⁹ nomenclature. MiGEC and MiXCR standard error correction
720 thresholds were used (including a minimal nucleotide quality score of 20 within the target gene
721 region) and only in-frame functional CDR3 sequences were included in downstream analyses.
722 Custom pipelines of Python scripts were then used to analyse and plot the MiXCR output and
723 proportional TRBV gene usage was calculated for each sample. Note that for visualisation, TRBV
724 genes that had a zero count at any given time-point were replaced with the minimum gene count
725 prior to log₁₀ transformation.

726 *Single cell RNA-sequencing of CD4⁺ T cells*

727 Cryopreserved PBMC from volunteers 313, 315 and 320 (first infection) and 1061, 1068 and 6032
728 (third infection) were prepared 2 days before infection (baseline) and 6 days post-treatment (T6)
729 during VAC063C. To undertake single cell RNA-sequencing these samples were thawed, washed,
730 counted and resuspended at a concentration of 3×10^6 cells ml⁻¹ in PBS supplemented with 2%
731 fetal bovine serum (heat inactivated and 0.22 µm filtered FBS Premium Plus, Gibco #16000044) and
732 5 mM EDTA (Life Technologies #AM9260G). Cells were then stained with surface antibodies exactly
733 as described above (see *Flow-sorting CD4⁺ T cell subsets*) but with the addition of TotalSeq-C
734 oligo-tagged barcoding antibodies that recognise CD298 and β2-microglobulin (a combination of
735 clones LNH-94 and 2M2, available from BioLegend). For each sample we flow-sorted 300,000 CD4⁺
736 T cells (CD3^{pos} CD4^{pos}) into 15 ml conical tubes containing 5 ml RPMI 1640 supplemented with 10%
737 FBS Premium Plus. At the same time we sorted an equal number of CD4⁺ T cells into 5 ml cold PBS
738 (containing 2% FBS and 5 mM EDTA) and re-acquired these on the cell sorter to check purity, which
739 was > 95% for every sample.

740 After sorting and purity checks, six individually barcoded samples were pooled (one pool for first
741 infection and a separate pool for third infection) and the concentration of each pool was carefully
742 measured and adjusted to 1262 cells µl⁻¹. Each pool was then loaded into 2 wells of an A Chip,
743 which itself was loaded onto a 10X Genomics Chromium Controller. Note that we intentionally
744 superloaded the controller in order to capture ~ 30,000 singlets per pool based on the workflow
745 described in Stoeckius *et al.*³² Captured cells were then tagged with 10X cell barcodes in GEMs,
746 cDNA was amplified and libraries were constructed according to the manufacturer's instructions
747 (Chromium single cell V(D)J reagent kit with feature barcoding technology for cell surface protein -
748 protocol CG000186 revision C). From each GEM three libraries were constructed and separately
749 indexed: i) the cell surface barcode, ii) 5' gene expression and iii) the T cell receptor α and β chains
750 (after amplification of the V(D)J regions). Following QC and quantification (using the Agilent

751 Bioanalyzer and TapeStation as well as Qubit) the libraries were pooled at a ratio of 8% cell surface,
752 84% gene expression and 8% V(D)J and then sequenced on a NovaSeq 6000 Illumina platform to
753 yield at least 66,000 150 bp PE reads per cell. In total we obtained 5931 million PE reads (2848 and
754 3083 million PE reads for first and third infection, respectively) of which 487 million PE reads (8.2%)
755 were derived from the cell surface library, 4858 million PE reads (81.9%) from the 5' gene expression
756 library and 586 million PE reads (9.9%) from the V(D)J library.

757 *Single cell RNA-sequencing analysis*

758 Cell Ranger multi (v6.0.2) was used to align 5' gene expression and V(D)J sequencing reads to the
759 GRCh38 reference genome. This initial step was performed independently for first and third
760 infection since both pools used the same set of six TotalSeq-C barcodes - C0251
761 (GTCAACTCTTTAGCG), C0252 (TGATGGCCTATTGGG), C0253 (TTCCGCCTCTCTTTG), C0254
762 (AGTAAGTTCAGCGTA), C0255 (AAGTATCGTTTCGCA) and C0256 (GGTTGCCAGATGTCA) (all
763 BioLegend). Feature-Barcode matrices were then loaded into R (v4.2.0) using Seurat (v4.3.0) and
764 oligo count matrices were generated from the cell surface library using CITE-seq-Count (v1.4.2)
765 (<https://doi.org/10.5281/zenodo.2590196>). These datasets were filtered to only include 10X cell
766 barcodes that were detected in both the 5' gene expression and cell surface libraries, and after
767 normalisation and scaling PCA-initialised tSNE was used to visualise the data (first seven principal
768 components, perplexity = 100). For each pool of samples, inspection of the oligo expression levels
769 revealed six large clusters that corresponded to single positive cells (or singlets). As such, we could
770 use nearest neighbour identification (PCA 1-6) and Louvain clustering to assign each singlet to a
771 sample and exclude cells with multiple oligo tags (doublets). At this stage the data from first and
772 third infection were combined, and a standard Seurat workflow was followed for quality control.
773 Briefly, we excluded cells with more than 2500 feature counts (or less than 200) and cells with more
774 than 5% mitochondrial transcripts. Data were log normalised and the top 2000 most variable
775 features were selected (after variance stabilisation) for computing of the principal components (PC).
776 Harmony¹⁰⁰ (v0.1.0) was used to integrate data and reduce individual variation, and Seurat's
777 wrapper for the Louvain algorithm (FindClusters) was used to cluster cells based on the first twelve
778 PC (with default settings at a resolution of 0.8). An initial pass of this analysis identified a persistent
779 and hyperexpanded cluster of TRBV11-3^{pos} CD4⁺ T cells. These cells were unique to v1068 (the only
780 CMV seropositive volunteer) and did not respond to malaria; we therefore excluded this cluster from
781 all downstream steps to avoid confounding signatures of malaria-induced activation.

782 Next differential cluster abundance was modelled using negative binomial regression with glm.nb()
783 from the MASS package. Time-point was fit as a categorical variable, p values were adjusted
784 (Benjamini-Hochberg method) and an FDR < 0.05 was considered significant. Slingshot¹⁰¹ was then
785 used to perform pseudotime analysis on Harmony-derived PC (default settings); the leaf node was
786 set to either cluster 10 or 11 (CD38^{hi} cells) but no trajectory passed through both clusters. Finally,
787 to analyse TCR diversity we used createHTOContigList() to filter and match Cell Ranger's
788 annotations on the assembled contigs to those extracted from scRepertoire¹⁰² (v1.8.0). V gene
789 usage (TRAV and TRBV) was analysed using standard immunarch (v0.9.0)
790 (<https://github.com/immunomind/immunarch>) workflows (excluding ambiguous assignments) and
791 the amino acid sequences of the TCR in each cluster were used to calculate their Gini coefficient
792 (using convenience functions). Data were visualised using ComplexHeatmap¹⁰³ or ggplot2.

793 *Processing whole blood for mass cytometry*

794 Venous blood was collected in K₂EDTA-coated vacutainers, stabilised within 30 minutes of blood
795 draw in whole blood stabilisation buffer (Cytodelics #hWBCS002) and stored at -80°C. For
796 antibody staining samples were quickly thawed in a 37°C water bath and then fixed and red cell
797 lysed for 15 minutes using a whole blood preservation kit (Cytodelics #hC002). Next cells were
798 permeabilised with Maxpar barcode permeabilisation buffer (Fluidigm #201057) and each sample
799 was barcoded using Cell-ID 20-plex palladium barcodes (Fluidigm #201060). Samples were then
800 pooled and stained with our T cell focussed surface antibody mix (see Supplementary Table 3) for
801 30 minutes. After washing, cells were fixed and permeabilised with the Maxpar nuclear antigen
802 staining buffer set (Fluidigm #201063) and incubated with the nuclear antibody mix for 45 minutes.
803 Cells were then washed and fixed for 10 minutes in 1.6% formaldehyde diluted in PBS
804 (ThermoFisher #28906). After a final round of washes, cells were resuspended at a concentration
805 of 3 x 10⁶ cells ml⁻¹ in 72.5 nM Cell-ID Intercalator Ir solution (Fluidigm #201192A) and stored
806 overnight at 4°C. Samples were acquired the next day on a freshly tuned Helios mass cytometer
807 (acquisition rate 300-500 events per second) using the WB injector and 10% EQ four element
808 calibration beads (140Ce, 151Eu, 165Ho and 175Lu, Fluidigm #201078).

809 *Mass cytometry data analysis*

810 The Fluidigm CyTOF software (version 6.7) generated FCS files, which were normalised¹⁰⁴ and
811 debarcoded¹⁰⁵ using the R package CATALYST¹⁰⁶. Samples were compensated using single stained
812 beads¹⁰⁷. After exclusion of normalisation beads and doublets we gated on CD45^{pos} CD3^{pos} T cells
813 using the Cytobank web portal (<https://www.cytobank.org>). We then inspected the intensity
814 distribution of each channel and removed those with low variance (CD16, CD69, CXCR5, GATA3,
815 RORγt, TCRγδ and TIM3). The remaining 30 markers were used for UMAP and FlowSOM clustering.
816 UMAP¹⁰⁸ was used to generate a 2D projection of this high-dimensional dataset. Here
817 phenotypic similarity of cells within and between populations is preserved in the Euclidean distance
818 of the projection. We used its R implementation in the scater¹⁰⁹ package, which in turn relies on
819 uwot (<https://www.github.com/jlmeville/uwot>). Features were scaled to unit variance and the 15
820 nearest neighbours were considered for embedding. UMAP coordinates were then exported for
821 visualisation using ggplot2. FlowSOM¹¹⁰ uses self-organising maps (SOM) to efficiently categorise
822 cytometry data into non-overlapping cell populations and was performed using CATALYST (default
823 parameters, target: 100 clusters, 50 metaclusters). After manual inspection we merged
824 two phenotypically similar clusters to avoid overclustering¹¹¹ and ended up with 49 discrete T
825 cell clusters. The R/Bioconductor package ComplexHeatmap was used to visualise T
826 cell phenotypes and the arcsine transformed signal intensity of each marker was independently
827 scaled using a 0-1 transformation across all clusters.

828 To analyse differential cluster abundance we used the workflow laid out by Nowicka *et*
829 *al.*¹¹² FlowSOM cluster cell counts were modelled linearly with time-point as a dependent
830 categorical variable and volunteer as a fixed effect using the diffcyt¹¹³ implementation of edgeR⁴⁷.
831 The edgeR functions automatically normalise cluster counts for the total number of cells and
832 improve statistical power by sharing information on cluster count variance between clusters.
833 Pairwise comparisons were performed relative to baseline, and clusters with an FDR < 0.05 and
834 absolute fold-change > 2 were deemed to vary significantly through time. We assessed differential

835 cluster abundance independently for volunteers receiving their first or third infection. We
836 also assessed whether marker expression varied significantly through time and to do this we
837 merged clusters belonging to the same T cell lineage according to their expression of CD4,
838 CD8, CD56, V δ 2 and V α 7.2. Adaptive CD4⁺ and CD8⁺ T cells were then split into naive, effector,
839 effector memory and central memory subsets based on their expression of the markers CD45RA,
840 CD45RO, CD57 and CCR7. All regulatory T cells (CD4^{pos} CD25^{hi} CD127^{neg}) were merged into a single
841 cluster. Linear models derived from the limma package, which is optimised for continuous data,
842 were then used to independently assess differential marker expression relative to baseline using
843 pairwise comparisons with moderated t-tests; a shift in median expression of at least 10% and an
844 FDR < 0.05 were required for significance. Results were visualised using ComplexHeatmap with
845 row-wise z-score transformed marker intensities shown for each lineage (or subset) of T cells.

846 *Meta-analysis of liver injury*

847 A surrogate dataset from Reuling *et al.*⁴⁹ was used to assess the risk of liver injury during a first-in-
848 life infection compared to re-challenge. We extracted data from every CHMI study that used the
849 3D7 *P. falciparum* clone (or its parental NF54 line), initiated infection via mosquito bite or direct
850 blood challenge and that had a treatment threshold based on thick smear positivity (estimated to
851 be at least 5000 parasites ml⁻¹ blood). This produced data for 95 volunteers across 7 CHMI studies.
852 Notably, Reuling *et al.* used longitudinal data to show that liver function test (LFT) abnormalities
853 peaked up to 6 days post-treatment in line with our own T6 time-point. And furthermore, in every
854 CHMI study (including our own) LFT abnormalities were graded using the same adaptation of the
855 WHO adverse event grading system. An LFT reading > 1.0 but < 2.5 times the upper limit of normal
856 was graded as mild; a reading > 2.5 but < 5.0 times the upper limit was graded moderate; and a
857 reading > 5.0 times the upper limit was graded severe. For ALT, the upper limit of normal was 35
858 or 45 units litre⁻¹ for female and male volunteers, respectively. Data from the 95 volunteers in Reuling
859 *et al.* and the 3 volunteers undergoing first infection in our VAC063C study were pooled for analysis
860 and we calculated a weighted peak parasitemia across the cohort by using the mean number of
861 parasites ml⁻¹ and the number of volunteers in each of the 8 CHMI studies. To statistically test
862 whether an abnormal ALT reading was more prevalent in the 98 volunteers experiencing their first
863 malaria episode compared to the 8 volunteers undergoing re-challenge (either second or third
864 infection) we used Barnard's test, which examines the association of two independent categorical
865 variables in a 2 x 2 contingency table. A p value below 0.05 was considered significant.

866 *Pearson correlation analysis*

867 To assess the relationship between liver injury, T cell activation, systemic inflammation and the
868 clinical symptoms of malaria we constructed a Pearson correlation matrix using our VAC063C
869 dataset. Importantly, this analysis was agnostic of infection number (all volunteers were included).
870 We input the concentration of ALT and the percentage of activated effector (effector memory) CD4⁺
871 T cells, regulatory T cells and cytotoxic (granzyme B^{pos}) T cells (all at T6); the fold-change of
872 lymphocytes, haemoglobin and all significant plasma analytes (those shown in Extended Data
873 Figure 3A), which were calculated at diagnosis or T6 (relative to baseline) according to their largest
874 absolute fold-change; the maximum parasite density and maximum core temperature (at any time-
875 point up to 48 hours post-treatment); and the titres of AMA1/MSP1-specific class-switched
876 antibodies (measured 28 days after challenge). All data were log₂ transformed and Pearson

877 correlation was performed in R using the corrplot function. Correlation coefficients were used for
878 unsupervised hierarchical clustering by Euclidean distance.

879 *In vitro cytotoxicity*

880 The hepatoma cell line HepG2 was kindly provided by Shaden Melhem (University of Edinburgh).
881 HepG2 cells were maintained at 37°C and 5% CO₂ in RPMI 1640 supplemented with 10% heat-
882 inactivated fetal bovine serum (FBS Premium Plus, Gibco #16000044), 1 x GlutaMAX (Gibco
883 #35050061), 100 units ml⁻¹ penicillin and 100 µg ml⁻¹ streptomycin (Gibco #15140122). Expansion
884 was performed in tissue culture treated culture flasks (Corning #430641U) and cells were detached
885 using TrypLE Express Enzyme (Gibco #12604013). For cytotoxicity assays, HepG2 cells were
886 seeded at a density of 5.5 x 10⁵ cells per well in 96 well tissue culture treated plates pre-coated
887 with Poly-D-Lysine (Gibco #A3890401) and incubated for 24 hours to allow formation of a confluent
888 monolayer.

889 The next day PBMC were thawed, washed, counted and resuspended at a concentration of 3 x 10⁶
890 cells ml⁻¹ in RPMI 1640 supplemented with 10% fetal bovine serum (FBS Premium Plus), 2 mM L-
891 Glutamine (#25030081), 1 mM sodium pyruvate (#11360070), 10 mM HEPES (#15630080), 500 µM
892 β-mercaptoethanol (#31350010) and 1 x MEM non-essential amino acids (#M7145) (all Gibco
893 except amino acids from Sigma-Aldrich). Cells were transferred to ultra low attachment plates
894 (Corning #3473) and stimulated with cell activation cocktail (BioLegend #423302) for 3 hours at
895 37°C and 5% CO₂ - the working concentration of PMA and ionomycin used was 40.5 nM and 669.3
896 nM, respectively. PBMC were then harvested, washed twice and added onto HepG2 monolayers
897 at increasing ratios of effector (PBMC) to target cells (HepG2). After 24 hours of co-culture the
898 release of lactate dehydrogenase (LDH) from damaged HepG2 cells was measured in the culture
899 supernatant using the CyQUANT LDH cytotoxicity assay according to the manufacturer's
900 instructions (Invitrogen #C20301). Background LDH release was quantified in wells containing only
901 HepG2 cells. Absorbance was read on a FLUOstar Omega plate-reader.

902 Acknowledgements

903 We thank Paul Sopp for T cell sorting during the VAC063 trial and Neil Ashley for support with single
904 cell RNA-sequencing. Flow-sorting, 10X Genomics and CyTOF data were generated within the flow
905 cytometry, single cell and mass cytometry facilities at the Weatherall Institute of Molecular Medicine
906 (University of Oxford), which are supported by MRC Human Immunology Unit core funding
907 (MC_UU_00008) and the Oxford Single Cell Biology Consortium (OSCBC). CD4⁺ T cell subset
908 RNAseq libraries were prepared and sequenced by the Edinburgh Clinical Research Facility at the
909 University of Edinburgh, which receives financial support from NHS Research Scotland (NRS).
910 Whole blood RNAseq libraries were prepared and sequenced by Edinburgh Genomics, which is
911 supported through core grants from NERC (R8/H10/56), MRC UK (MR/K001744/1) and BBSRC
912 (BB/J004243/1). We would like to extend our thanks to the VAC063 and VAC069 clinical and
913 laboratory teams for assistance, and to all of the volunteers who participated in this study.

914 Funding


915 The VAC063 trial was supported in part by the Office of Infectious Diseases, Bureau for Global
916 Health, U.S. Agency for International Development (USAID) under the terms of the Malaria Vaccine
917 Development Program (MVDP) contract AID-OAA-C-15-00071, for which Leidos, Inc. was the prime
918 contractor. The opinions expressed herein are those of the authors and do not necessarily reflect
919 the views of the USAID. The VAC063 trial was also supported in part by the National Institute for
920 Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those
921 of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
922 The VAC069 trial was supported by funding from the European Union's Horizon 2020 research and
923 innovation programme under grant agreement for MultiViVax (number 733073). The single cell RNA-
924 sequencing experiment was supported by the Human Infection Challenge Network for Vaccine
925 Development (HIC-Vac) funded by the GCRF Networks in Vaccines Research and Development,
926 which was co-funded by the MRC and BBSRC. This UK-funded award is part of the EDCTP2
927 programme supported by the European Union. DMS is the recipient of a Darwin Trust of Edinburgh
928 PhD studentship and FB, ACH and NLS are each the recipient of a Wellcome Trust PhD studentship
929 (grant no. 203764/Z/16/Z, 226857/Z/23/Z and 204511/Z/16/A, respectively). SJD was the recipient
930 of a Wellcome Trust Senior Fellowship (grant no. 106917/Z/15/Z) and is a Jenner Investigator. This
931 project was supported by the Wellcome Trust-University of Edinburgh Institutional Strategic
932 Support Fund, and PJS is the recipient of a Sir Henry Dale Fellowship jointly funded by the
933 Wellcome Trust and the Royal Society (grant no. 107668/Z/15/Z).

934 Conflict of interest

935 The authors have no conflict of interest to declare and the funders had no role in study design, data
936 interpretation or the decision to submit the work for publication.

937 Data availability

938 All bulk RNAseq data (whole blood and sorted T cell subsets) have been deposited in NCBI's Gene
939 Expression Omnibus and are accessible through GEO SuperSeries accession number GSE172481.
940 Single cell RNA-sequencing data have also been deposited in NCBI's Gene Expression Omnibus
941 and are available through accession number GSE275092. Bulk TCR β sequencing data have been
942 deposited in the European Nucleotide Archive and are available through accession number
943 PRJEB71976. And CyTOF (mass cytometry) data have been deposited at flowrepository.org - these
944 can be accessed through experiment numbers FR-FCM-Z47Z (VAC063C); FR-FCM-Z3HA
945 (VAC069A); and FR-FCM-Z465 (VAC069B).



946 **Figure 1.** The risk of severe malaria decreases exponentially with exposure. Data were extracted
947 from Gonçalves *et al.*¹ to examine the frequency of severe (A) or complicated (B) malaria during the
948 first 14 infections of life in infants living in a hyperendemic setting. We performed maximum
949 likelihood estimation to select the best model fit for these data; the black line shows the best fit and
950 grey shading represents the 95% confidence intervals. In both cases, an exponential decay
951 provided a better fit than either a linear decay or constant risk. In (A) n = 102 severe episodes and
952 in (B) n = 199 complicated episodes of malaria (see Extended Data Figure 1 for case imputation
953 and model performance). (C-G) Healthy malaria-naïve adults were infected up to three times with
954 *P. falciparum* (clone 3D7) by direct blood challenge. Repeated sampling before, during and after
955 each infection allowed us to track the development of disease tolerance in real-time. (C) Parasite
956 growth curves for first, second and third infection; each line represents a volunteer and lines are
957 colour-coded by infection number. Parasite density was measured in peripheral blood by qPCR
958 every 12 hours. The grey box represents the lower limit of quantification (20 parasites ml⁻¹) and the
959 treatment threshold of 10,000 parasites ml⁻¹ is denoted by the black line. Maximum core body
960 temperature (D) and minimum haemoglobin (E) recorded during each infection (up to 48 hours post-
961 treatment). Each symbol represents one volunteer with a line shown at the median. Grey shading
962 indicates normal range (115 - 165 g litre⁻¹ haemoglobin for female and 130 - 180 g litre⁻¹ haemoglobin
963 for male volunteers). Lymphocytes (F) and platelets (G) were quantified in circulation the day before
964 infection (baseline), 6 days after challenge (c6), at the peak of infection (diagnosis) and approx. 1
965 month after drug treatment (convalescence). Boxplots show the median and IQR, and whiskers
966 represent the 95% confidence intervals. Sample size (n) is 10 for first and second infection and n =
967 6 for third infection. There was no statistically significant difference between groups using a
968 significance threshold of 5% (Kruskal-Wallis test).






figure two

969 **Figure 2.** Infection triggers a hardwired emergency host response. **(A)** RNA-sequencing was used
970 to identify differentially expressed genes in whole blood at diagnosis (versus baseline) ($\text{adj } p < 0.05$
971 and > 1.5 fold-change). ClueGO was then used for functional gene enrichment analysis and placed
972 significant GO terms into functional groups by relatedness. Shown are the leading GO terms from
973 15 non-redundant groups with the lowest $\text{adj } p$ value in first infection. The same GO terms are
974 plotted in second and third infection (note that each infection was analysed independently). **(B)**
975 Radar plots (or 3-way volcano plots) show the number of differentially expressed genes in whole
976 blood between each infection - the left plot compares all baseline samples and the right plot
977 diagnosis. Dashed lines represent the centre-point for each volcano plot and the position of each
978 dot relative to this line shows up- or downregulation. There were no differentially expressed genes
979 in any of the six pairwise comparisons ($\text{adj } p < 0.05$ and > 1.5 fold-change). **(C)** 39 plasma analytes
980 were quantified before and during each infection using a highly multiplexed bead-based assay. The
981 \log_2 fold-change of each analyte is shown relative to baseline on day 6 and 8 post-challenge (c6
982 and c8, respectively) and at diagnosis. Analytes are ordered by \log_2 fold-change and are shown in
983 bold if they varied significantly during both second and third (compared to first) infection ($\text{adj } p <$
984 0.05 by linear regression with Benjamini-Hochberg correction for multiple testing). In (A-B) $n = 10$
985 (first infection), 9 (second infection) and 6 (third infection). v1040 was excluded from RNA-
986 sequencing analysis in second infection because their baseline sample failed QC. In (C) $n = 9$ (first
987 and second infection) and 5 (third infection). v1040 was excluded from plasma analysis because all
988 samples failed QC.






figure three

989 **Figure 3.** A single malaria episode attenuates T cell activation. **(A)** The percentage of activated
990 CD38^{hi} effector or effector memory (EM) CD4⁺ T cells was analysed by flow cytometry at baseline
991 (grey dots) and 6 days after parasite clearance (coloured dots) during the VAC063C study. Data are
992 shown for volunteers undergoing their first, second or third infection of life (see Supplementary Data
993 File 1 for gating strategies). **(B)** The percentage of activated CD38^{hi} effector or effector memory
994 CD4⁺ T cells at baseline (grey dots) and 6 days after parasite clearance (coloured dots) during the
995 VAC069 study. **(C-D)** RNA-sequencing was used to identify differentially expressed genes in flow-
996 sorted effector (effector memory) CD4⁺ T cells (T6 versus baseline) in first and third infection during
997 VAC063C (adj p < 0.05 and > 1.5 fold-change). The heatmaps in (C) show the log₂ fold-change of
998 markers of T cell activation and exhaustion and the master transcription factors that shape T cell
999 fate (plus associated chemokine receptors). Non-significant genes are displayed with a log₂ fold-
1000 change of zero and square brackets indicate that common gene names have been used. The
1001 stacked circular bar chart in (D) shows the log₂ fold-change of cytokines and cytotoxic effector
1002 molecules. **(E)** Correlation between log₁₀ transformed T cell receptor beta variable (TRBV) gene
1003 frequency at baseline and 28 days post-challenge (convalescence) showing linear regression (black
1004 line) with 99% confidence intervals (grey shaded area). These data represent V gene usage across
1005 the entire T cell compartment and were obtained after one or two malaria episodes from volunteers
1006 who were subsequently infected for a third time during VAC063C. In (A) n = 3 for first infection, n =
1007 2 for second infection and n = 6 for third infection. In (B) n = 8 for first infection and n = 3 for second
1008 infection. In (C-D) n = 2 or 3 for first infection (T6 and baseline, respectively) and n = 6 for third
1009 infection (v313 was excluded at T6 because this sample failed QC). In (E) n = 5 in first and second
1010 infection (v1065 convalescence samples failed QC).









figure four

1011 **Figure 4.** Stem-like memory CD4⁺ T cells respond to re-challenge. Droplet-based single cell RNA-
1012 sequencing was carried out during VAC063C on flow-sorted CD4⁺ T cells obtained at baseline and
1013 T6 from volunteers undergoing their first or third infection of life. **(A)** Data from all volunteers and
1014 time-points was concatenated for UMAP analysis and FlowSOM identified 13 discrete clusters of
1015 CD4⁺ T cells across the dataset (each given a unique colour). **(B)** Heatmap showing the differential
1016 abundance of non-naïve CD4⁺ T cell clusters at T6 (versus baseline) in first and third infection (FDR
1017 < 0.05). Note that non-significant clusters are shown with a log₂ fold-change of zero and the
1018 identification of non-naïve clusters is shown in Extended Data Figure 5. **(C)** Dot plot showing
1019 differentially expressed signature genes in clusters 10 and 11 (adj p < 0.05). Square brackets
1020 indicate that common gene names have been used. **(D)** Trajectory inference with Slingshot revealed
1021 clusters 10 and 11 as discrete non-overlapping endpoints of CD4⁺ T cell activation and
1022 differentiation (analysis was performed on concatenated data and CD38^{hi} cells were set as the
1023 endpoint; Slingshot identified two possible non-overlapping routes). **(E)** Spearman correlation
1024 matrix showing shared V gene usage (TRAV and TRBV) across all CD4⁺ T cell clusters (the order of
1025 features was determined by unsupervised hierarchical clustering). **(F)** Gini plot showing the equality
1026 of V gene usage in each CD4⁺ T cell cluster in first and third infection; zero denotes perfect equality,
1027 which indicates a diverse TCR repertoire. **(G)** Class-switched antibodies (IgG) recognising the
1028 malaria antigens MSP1 and AMA1 were quantified in serum by ELISA at baseline (grey dots) and
1029 one month after challenge (coloured dots). Samples were obtained from volunteers undergoing their
1030 first, second or third infection during VAC063A, VAC063B and VAC063C, respectively. In (A-F) n =
1031 3 for first and third infection whereas in (G) n = 10 for first and second infection and n = 6 in third
1032 infection.




1033 **Figure 5.** Cytotoxic T cells are silenced for a minimum 8 months. Whole blood was preserved within
1034 30 minutes of blood draw at baseline, diagnosis and T6 during VAC063C as well as 45 days post-
1035 challenge (convalescence). Samples were stained with a T cell focussed antibody panel (see
1036 Supplementary Table 3) and acquired on a Helios mass cytometer. After exclusion of
1037 normalisation beads and doublets we gated on CD45^{pos} CD3^{pos} T cells for downstream steps. **(A)**
1038 Data from all volunteers and time-points was concatenated for UMAP analysis and FlowSOM
1039 identified 49 discrete clusters of T cells across the dataset (each given a unique colour). The major
1040 T cell subsets are labelled according to expression of lineage, memory and activation markers. **(B)**
1041 UMAP showing the T cell clusters that are differentially abundant at T6 (versus baseline) in first and
1042 third infection (FDR < 0.05 and > 2 fold-change). Clusters that are not significant are shown in black.
1043 **(C)** The mean frequency of each T cell cluster that is differentially abundant in first and/or third
1044 infection is shown as a proportion of all CD45^{pos} CD3^{pos} T cells at T6. **(D)** Pies show the relative size
1045 of each differentially abundant cluster. **(E)** Heatmap showing the normalised median expression
1046 values of all markers used for clustering in each of the differentially abundant T cell clusters. The
1047 order of features was determined by unsupervised hierarchical clustering. Colour codes to the left
1048 of the heatmap indicate cluster identity and show whether clusters were significant in first infection
1049 or first and third infection. Note that no cluster was unique to third infection. In (A-E) n = 3 for first
1050 infection and n = 6 for third infection.

	data source	number of volunteers	perpetuity abnormal ALI	severity			max. parasite density*
				mild	moderate	severe	
first infection	Reuling <i>et al.</i>	95	70	40	16	14	17,587
	VAC063C	3	2	0	0	2	
	total	98	72	40	16	16	


re-challenge	VAC063C	8	2	2	0	0	36,630
--------------	---------	---	---	---	---	---	--------

*weighted mean number of parasites per ml blood


C




B



D



1051 **Figure 6.** Controlling T cell activation protects host tissues. **(A)** A surrogate dataset from Reuling et
1052 *al.*⁴⁹ was used to extract information on the frequency and severity of abnormal alanine
1053 aminotransferase (ALT) during a first-in-life infection (up to 6 days post-treatment). All volunteers
1054 were infected with *P. falciparum* (3D7 or NF54) as part of a CHMI trial that used equivalent end-
1055 points to our own study and in every case abnormal ALT was scored using the same adaptation of
1056 the WHO adverse event grading system (see methods). Data from 95 volunteers in Reuling et al.
1057 (those enrolled in the EHMI-3, LSA-3, EHMI-8B, EHMI-9, ZonMw2, TIP5 and CHMI-trans1 studies)
1058 and the 3 first infection volunteers in VAC063C were pooled for analysis. **(B)** Frequency and severity
1059 of liver injury; Barnard's test was used to statistically determine whether an abnormal ALT reading
1060 was more prevalent during a first-in-life infection compared to second or third infection (a p value
1061 below 0.05 was considered significant). **(C)** Pearson correlation matrix showing the fold-change of
1062 differentially abundant plasma analytes, lymphocytes and haemoglobin during VAC063C. Fold-
1063 change was calculated either at diagnosis or T6 (relative to baseline) according to when this was
1064 largest for each feature. Also included is maximum parasite density, maximum core temperature
1065 (up to 48 hours post-treatment) and class-switched antibody titres (28 days after challenge). Finally,
1066 circulating ALT is shown at T6 together with the frequency of activated (CD38^{hi}) effector (effector
1067 memory) CD4⁺ T cells, regulatory T cells and cytotoxic T cells (defined as granzyme B^{pos}). All data
1068 were log2 transformed and the order of features was determined by unsupervised hierarchical
1069 clustering. **(D)** Peripheral blood mononuclear cells (PBMC) were isolated during VAC063C from
1070 volunteers undergoing their first infection of life, re-stimulated *in vitro* with PMA/ionomycin and co-
1071 cultured with HepG2 cells for 24 hours. Cytotoxicity was measured by the release of lactate
1072 dehydrogenase (LDH). Experiments were performed using baseline and T6 samples, and data are
1073 shown as baseline subtracted values (i.e. absorbance at T6 minus absorbance at baseline). Curves
1074 were fit using a cubic polynomial function (the shaded areas represent 95% confidence intervals).
1075 Note that LDH release was specific to HepG2 cells as shown in Extended Data Figure 7B and all
1076 assays were run in duplicate. In (A-B) n = 98 for first infection and n = 8 for re-challenge (2 second
1077 infection and 6 third infection). In (C) n = 10 (3 first infection, 2 second infection and 5 third infection)
1078 and in (D) n = 3 (first infection only).

A

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.19.21262298>; this version posted October 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.





B

model	SE (I)	β_1	SE (β_1)	logL	AIC
constant risk	0.033	na	na	-33.73	69.47
	0.074	na	na	-40.85	83.70
linear decay	0.037	0.002	0.0002	-29.39	62.79
	0.089	0.006	0.0002	-29.93	63.85
exponential decay	0.045	0.118	0.0398	-28.59	61.18
	0.101	0.139	0.0306	-28.11	60.21
exponential decay (GLM)	0.053	0.122	0.0409	-28.59	61.17
	0.130	0.148	0.0323	-28.16	60.32





I = intercept
 SE (I) = SE intercept
 β_1 = order of infection
 SE (β_1) = SE order of infection
 logL = log likelihood
 AIC = akaike information criterion
 GLM = generalised linear model

top no. = risk of *severe* malaria
 bottom no. = risk of complicated malaria


1079 **Extended Data Figure 1.** The risk of severe malaria decreases exponentially with exposure. Data
1080 were extracted from Gonçalves *et al.*¹ to examine the frequency of severe or complicated malaria
1081 during the first 14 infections of life in infants living in a hyperendemic setting. **(A)** We first plotted
1082 the total number of cases of malaria (including mild or uncomplicated episodes) and used least
1083 squares regression to impute missing values (for infection number 9, 11, 12 and 13). Imputed values
1084 are shown as a grey triangle whereas filled circles indicate data as reported by Gonçalves *et al.* The
1085 total number of children experiencing at least 1 episode of malaria was $n = 715$. **(B)** We then plotted
1086 the incidence of severe or complicated malaria at each order of infection (as shown in Figure 1A-B)
1087 and performed maximum likelihood estimation to select the best model fit for these data; log
1088 likelihood (logL) and AIC both show that an exponential decay in risk provides the best fit.



1089 **Extended Data Figure 2.** Systemic inflammation is not attenuated upon re-challenge. **(A)**
1090 Proportion of eosinophils, lymphocytes, monocytes and neutrophils in whole blood at baseline and
1091 diagnosis. The mean frequency is shown for each time-point and infection. Note that the loss of
1092 lymphocytes at diagnosis is comparable in all three infections. **(B)** RNA-sequencing was used to
1093 identify differentially expressed genes in whole blood at diagnosis (versus baseline) (adj p < 0.05
1094 and > 1.5 fold-change). Volcano plots show all differentially expressed genes (coloured dots) and
1095 the dashed lines represent the significance/fold-change cut-offs (genes that are not significant are
1096 shown in grey). The top 10 differentially expressed genes (lowest adj p) in each infection are labelled
1097 (first, second and third infection were analysed independently). **(C)** The log₂ fold-change of
1098 signature genes associated with interferon signaling and type I inflammation are shown at diagnosis
1099 (versus baseline) in first, second and third infection. Square brackets indicate that common gene
1100 names have been used. **(D)** Linear regression was used to identify plasma analytes that vary
1101 significantly between infections at diagnosis. Multiple test correction was performed using the
1102 Benjamini-Hochberg method and analytes that were significant in both second and third infection
1103 (versus first infection) are displayed (adj p < 0.05). Box (median and IQR) and whisker (1.5x upper
1104 or lower IQR) plots are shown with outliers as dots. In (A) n = 10 (first and second infection) and n
1105 = 6 (third infection). In (B-C) n = 10 (first infection), n = 9 (second infection) and n = 6 (third infection).
1106 v1040 was excluded from RNA-sequencing analysis in second infection because their baseline
1107 sample failed QC. In (D) n = 9 (first and second infection) and n = 5 (third infection). v1040 was
1108 excluded from plasma analysis because all samples failed QC.


A**B****C****D**

1109 **Extended Data Figure 3.** The acute phase response is followed by proliferation in first infection.
1110 **(A)** Mixed-effects models and linear regression were used to identify plasma analytes that vary
1111 significantly at diagnosis and/or T6 across the entire VAC063C dataset (all volunteers regardless of
1112 infection number). Kenward Roger approximation was used to calculate p values and multiple test
1113 correction was performed using the Benjamini-Hochberg method; significance ($\text{adj } p < 0.05$) is
1114 indicated by coloured box plots (purple at diagnosis and turquoise at T6). Box (median and IQR)
1115 and whisker (1.5x upper or lower IQR) plots are shown with outliers as dots. **(B)** RNA-sequencing
1116 was used to identify differentially expressed genes in whole blood at diagnosis and T6 during first
1117 infection (versus baseline) ($\text{adj } p < 0.05$ and > 1.5 fold-change). Volcano plots show all differentially
1118 expressed genes (coloured dots) and the dashed lines represent the significance/fold-change cut-
1119 offs (genes that are not significant are shown in grey). The top 10 differentially expressed genes
1120 (lowest $\text{adj } p$) at each time-point are labelled. **(C)** Differentially expressed genes at T6 and diagnosis
1121 were combined for GO analysis of first infection and ClueGO was used to construct a merged
1122 functional gene ontology network. Each node represents a GO term and nodes are coloured
1123 according to whether their associated genes were majoritively ($> 60\%$) derived from the diagnosis
1124 or T6 time-point. GO terms that were shared between time-points are coloured grey (see methods).
1125 Four leading GO terms (each from a unique functional group) are labelled for each time-point. **(D)**
1126 Heatmaps show differentially expressed genes at diagnosis and T6 (versus baseline) during first
1127 and third infection ($\text{adj } p < 0.05$ and > 1.5 fold-change). The \log_2 fold-change of key genes
1128 associated with each phase of the cell cycle is shown. Non-significant genes are displayed with a
1129 \log_2 fold-change of zero. In (A) $n = 10$ (3 first infection, 2 second infection and 5 third infection).
1130 v1040 was excluded from plasma analysis because all samples failed QC. In (B - C) $n = 3$ (first
1131 infection only) and in (D) $n = 3$ (first infection) and $n = 6$ (third infection).





extended data figure 4

1132 **Extended Data Figure 4.** Re-challenge does not induce CD4⁺ T cell anergy, exhaustion or clonal
1133 deletion. **(A)** Healthy malaria-naïve adults were infected up to two times with *P. vivax* (clone PvW1)
1134 by direct blood challenge during the VAC069 study. Parasite growth curves are shown for first and
1135 second infection; each line represents a volunteer and lines are colour-coded by infection number.
1136 Parasite density was measured in peripheral blood by qPCR every 12 - 24 hours. The grey box
1137 represents the lower limit of quantification (20 parasites ml⁻¹) and the treatment threshold of 10,000
1138 parasites ml⁻¹ is denoted by the black line. **(B)** RNA-sequencing was used to analyse transcriptional
1139 regulation of fatty acid β-oxidation, the tricarboxylic acid (TCA) cycle and oxidative phosphorylation
1140 (oxphos) in flow-sorted effector (effector memory) CD4⁺ T cells during first infection with *P.*
1141 *falciparum* (VAC063C). The circular bar charts show the log₂ fold-change of each major enzyme
1142 involved in fatty acid β-oxidation and the TCA cycle clockwise in reaction order 6 days after parasite
1143 clearance (T6 versus baseline). The vertical bar chart shows the proportion of oxphos enzymatic
1144 subunits that are transcriptionally upregulated at T6 - all subunits required to form complex I to IV
1145 in the electron transport chain and ATP synthase are shown. The key molecules that connect these
1146 metabolic pathways are labelled. **(C - D)** RNA-sequencing was used to identify differentially
1147 expressed genes in flow-sorted effector (effector memory) CD4⁺ T cells in first and third infection
1148 during VAC063C (T6 versus baseline) (adj p < 0.05 and > 1.5 fold-change). Heatmaps show the
1149 log₂ fold-change of (C) hallmark genes indicating T cell anergy or quiescence and (D) markers of
1150 activation-induced cell death. **(E)** Flow-sorted regulatory T cells (CD4^{pos} CD25^{hi} CD127^{neg}) were also
1151 analysed by RNA-sequencing to identify differentially expressed genes relating to their activation
1152 and suppressor function (T6 versus baseline) in first and third infection (adj p < 0.05 and > 1.5 fold-
1153 change). **(F)** RNA-sequencing was used to identify differentially expressed genes in whole blood at
1154 diagnosis and T6 (relative to baseline) in first and third infection during VAC063C (adj p < 0.05 and
1155 > 1.5 fold-change). Signature genes associated with T cell activation, T_H1 differentiation and
1156 cytokine production are shown. In (A) n = 8 for first infection and n = 3 for second infection. In (B -
1157 E) n = 2 or 3 for first infection (T6 and baseline, respectively) and n = 6 for third infection (v313 was
1158 excluded at T6 because this sample failed QC). In (F) n = 3 for first infection and n = 6 for third
1159 infection. In (C-F) non-significant genes are displayed with a log₂ fold-change of zero.




B

	aligned reads	mapped to genome	mapped to transcriptome	single cells	median reads per cell	median genes per cell	total genes detected	median UMIs per cell
first infection	2.021x10 ⁹	90%	75%	23,227	77,682	954	20,848	3,011
third infection	2.026x10 ⁹	87%	73%	26,891	67,914	922	21,042	2,676




1160 **Extended Data Figure 5.** Activated CD4⁺ T cells bifurcate along the TCF1/BLIMP1 axis. **(A)**
1161 VAC063C single cell RNA-sequencing workflow: each sample of flow-sorted CD4⁺ T cells was
1162 barcoded using TotalSeq-C oligo-tagged antibodies; samples from all volunteers and time-points
1163 were pooled (separately for first and third infection); and pooled samples were superloaded onto a
1164 10X Chromium Controller (we aimed to capture 30,000 singlets per pool). Gel beads in emulsion
1165 (GEMs) encapsulating a single cell (or doublets) were then generated and from each GEM three
1166 libraries were produced: i) the cell surface barcode, ii) 5' gene expression and iii) T cell receptor
1167 (after amplification of the V(D)J regions). Libraries were pooled at the specified ratios and
1168 sequenced. Finally, we used PCA-based clustering to debarcode all samples and remove doublets
1169 (see methods). **(B)** Cell Ranger was used to align 5' gene expression and V(D)J sequencing reads
1170 (independently for first and third infection). Shown is the output of Cell Ranger after removing
1171 doublets and performing QC. **(C - F)** Data from all volunteers and time-points was concatenated for
1172 UMAP analysis. The expression intensity of markers for memory (C), activation (D) and T_{FH}
1173 differentiation (E) are shown across the UMAP. The blue line represents the split between naive and
1174 memory cells whereas the green line represents the split between memory and activated cells. In
1175 (F) the expression intensity of the master transcription factors associated with terminal
1176 differentiation (BLIMP1) versus the maintenance of stem-like properties (TCF1) are shown. In all
1177 cases, each UMAP is equivalent to those shown in Figure 4 (for cross-reference) and square
1178 brackets indicate that common gene names have been used. **(G)** Proposed model of T cell
1179 activation during a first-in-life malaria episode. The maintenance of stem-like T cells is essential for
1180 long-lived memory; this requires sustained expression of TCF1 to repress BLIMP1 and prevent the
1181 terminal differentiation of short-lived effector cells. In (A - F) n = 3 for first and third infection.

A




B




1182 **Extended Data Figure 6.** Cytotoxic T cells are silenced after a single malaria episode. **(A)** Stacked
1183 bar chart showing the frequency of activated ($CD38^{hi} Bcl2^{lo}$) T cells at baseline, diagnosis and T6
1184 as well as 45 days post-challenge (convalescence) during VAC063C. Each bar represents one
1185 volunteer and individual T cell clusters are colour-coded to match Figure 5 (note that only
1186 differentially abundant clusters are included). The major $CD4^{+}$ and $CD8^{+}$ T cell clusters with
1187 cytotoxic features are highlighted with a black border in the key to the left of the plot. **(B)** Differential
1188 marker expression through time in each major T cell subset. First, T cell clusters belonging to the
1189 same lineage were merged and then $CD4^{+}$ and $CD8^{+}$ T cells were split into naive, effector, effector
1190 memory (EM) and central memory (CM) subsets. Next, linear models were used to independently
1191 assess differential marker expression in each subset at each time-point (relative to baseline); a shift
1192 in median expression of at least 10% and an $FDR < 0.05$ were required for significance. Shown are
1193 all subset/marker pairs that were called as significant at T6 and data are presented as row-wise z-
1194 score marker intensities. Colour codes to the left of the heatmap indicate whether markers were
1195 differentially expressed during first infection, third infection or both infections.


A



B



C



1196 **Extended Data Figure 7.** Raised serum transaminases are unique to first infection. **(A)** Blood
1197 chemistry measured the concentration of alanine aminotransferase (ALT) through infection and
1198 convalescence in the VAC063C study (baseline, 6 days post-challenge (c6), diagnosis, 6 - 18 days
1199 after drug treatment (T6 - T18) and 45 or 90 days post-challenge (convalescence 1 and 2,
1200 respectively)). Each line represents one volunteer and lines are colour-coded by infection number.
1201 **(B - C)** Peripheral blood mononuclear cells (PBMC) were isolated during VAC063C from volunteers
1202 undergoing their first infection of life, re-stimulated *in vitro* with PMA/ionomycin and co-cultured
1203 with HepG2 cells for 24 hours. Cytotoxicity was measured by the release of lactate dehydrogenase
1204 (LDH). **(B)** PBMC were co-cultured with or without HepG2 cells to determine their relative
1205 contribution to LDH release. **(C)** PBMC isolated at baseline (grey) or T6 (turquoise) were co-cultured
1206 with HepG2 cells at different effector to target cell ratios. Each plot represents the raw data from
1207 one volunteer, the black line shows the mean absorbance in control wells (HepG2 cells only) and
1208 volunteers are ordered according to their frequency of activated cytotoxic CD4⁺ T cells at T6
1209 (highest to lowest (top to bottom) - see Extended Data Figure 6A). In **(A)** n = 11 (3 first infection, 2
1210 second infection and 6 third infection). In **(B)** a representative experiment is shown and in **(C)** n = 3
1211 (first infection only). Note that all cytotoxicity assays were performed in duplicate or triplicate and
1212 curves were fit using a cubic polynomial function (the shaded areas represent 95% confidence
1213 intervals).

1214 **Supplementary Data File 1.** Gating strategy for sorting CD4⁺ T cell subsets during VAC063C.
1215 CD4⁺ T cells were sorted *ex vivo* (within 2 hours of blood draw) into TRIzol for downstream RNA-
1216 sequencing - cells with a naive, effector (effector memory) or regulatory phenotype were sorted as
1217 shown at baseline and T6. Note that we did not use CD38 for sorting but subsequently used
1218 this marker to assess the level of activation within each subset at both time-points.

1219 **Supplementary Data File 2.** T cell receptor V gene usage in CD4⁺ T cell clusters. Droplet-based
1220 single cell RNA-sequencing was carried out during VAC063C on flow-sorted CD4⁺ T cells obtained
1221 at baseline and T6 from volunteers undergoing their first or third infection of life. Data from all
1222 volunteers and time-points was concatenated to examine V gene usage (in TCR α and TCR β chains)
1223 in each cluster. Note that clusters are colour-coded exactly as shown in Figure 4 and it is clusters
1224 10 (self-renewal) and 11 (terminal differentiation) that are activated (CD38^{hi}) by malaria (n = 3 in first
1225 and third infection).

1226 **Supplementary Data File 3.** T cell cluster phenotypes by mass cytometry. Heatmap showing the
1227 normalised median expression values of all markers used for clustering in each of the 49 T cell
1228 clusters. Names were assigned manually using activation, lineage and memory markers to broadly
1229 categorise each T cell cluster; when more than one cluster was placed into the same category (e.g.
1230 activated EM CD4) clusters were given an accessory label to highlight their unique phenotype or
1231 property (e.g. T-bet^{lo} Eomes^{neg}). The order of features was determined by unsupervised hierarchical
1232 clustering.

1233 **Supplementary Data File 4.** T cell cluster frequencies by mass cytometry. Each cluster is shown
1234 as a proportion of all CD45^{pos} CD3^{pos} T cells at each time-point. Clusters are shown in the same
1235 order as Supplementary Data File 3 (left to right and top to bottom). Box (median and IQR) and
1236 whisker (1.5x upper or lower IQR) plots are shown (with outliers as dots) and significance (FDR <
1237 0.05 and > 2 fold-change) is indicated by colour (dark blue for first infection and bright blue for
1238 third). In all plots n = 3 for first infection and n = 6 for third infection.

1239 **Supplementary Table 1.** Demographics of volunteers infected and re-challenged with *Plasmodium*
1240 *falciparum* (3D7) during VAC063A-C; includes genetic and non-genetic variables known to
1241 influence human immune variation *in vitro*. Also shown is the parasite multiplication rate (detailed
1242 methodology for the modelling of qPCR data can be found in Minassian *et al.*⁸¹) and maximum
1243 circulating parasite density. There were no statistically significant differences between first, second
1244 and third infection (Kruskal-Wallis test, p = 0.3240 for parasite multiplication rate and p = 0.5975
1245 for maximum parasite density).

1246 **Supplementary Table 2.** Signature genes associated with terminal differentiation and self-renewal
1247 in CD4⁺ T cells. Tab one lists the signature genes for each of the 13 clusters of CD4⁺ T cells identified
1248 by single cell RNA-sequencing during VAC063C. Note that clusters are colour-coded exactly as
1249 shown in Figure 4 and for each cluster genes are ordered by adj p value. Tab two lists the
1250 differentially expressed genes identified by direct pairwise comparison between activated (CD38^{hi})
1251 clusters 10 and 11. Genes that are more highly expressed in cluster 10 have a positive log2 fold-
1252 change. Note that differential gene expression analysis was performed across the entire dataset
1253 (i.e. data from all volunteers and time-points was concatenated) (n = 3 in first and third infection).

1254 **Supplementary Table 3.** Mass cytometry antibody panel for T cell fate and function in VAC063C;
1255 includes information on antibody clone, source and heavy metal conjugate.

1256 **Supplementary Table 4.** Coefficient and p values underlying the Pearson correlation matrix shown
1257 in Figure 6C.

1258 References

- 1259 1. Goncalves, B.P. *et al.* Parasite burden and severity of malaria in Tanzanian children. *N Engl*
1260 *J Med* **370**, 1799-1808 (2014).
1261
- 1262 2. Moxon, C.A., Gibbins, M.P., McGuinness, D., Milner, D.A., Jr. & Marti, M. New Insights into
1263 Malaria Pathogenesis. *Annu Rev Pathol* **15**, 315-343 (2020).
1264
- 1265 3. Snow, R.W. & Marsh, K. New insights into the epidemiology of malaria relevant for disease
1266 control. *Br Med Bull* **54**, 293-309 (1998).
1267
- 1268 4. Snow, R.W. *et al.* Risk of severe malaria among African infants: direct evidence of clinical
1269 protection during early infancy. *J Infect Dis* **177**, 819-822 (1998).
1270
- 1271 5. Doolan, D.L., Dobano, C. & Baird, J.K. Acquired immunity to malaria. *Clin Microbiol Rev* **22**,
1272 13-36 (2009).
1273
- 1274 6. McLean, F.E. *et al.* Detection of naturally acquired strain-transcending antibodies against
1275 rosetting *Plasmodium falciparum* strains in humans. *bioRxiv*, 2024.2001.2011.575252
1276 (2024).
1277
- 1278 7. Tuju, J. *et al.* Antigenic cartography of immune responses to *Plasmodium falciparum*
1279 erythrocyte membrane protein 1 (PfEMP1). *PLoS Pathog* **15**, e1007870 (2019).
1280
- 1281 8. Cumnock, K. *et al.* Host Energy Source Is Important for Disease Tolerance to Malaria. *Curr*
1282 *Biol* **28**, 1635-1642 e1633 (2018).
1283
- 1284 9. Ramos, S. *et al.* Renal control of disease tolerance to malaria. *Proc Natl Acad Sci U S A* **116**,
1285 5681-5686 (2019).
1286
- 1287 10. Wang, A. *et al.* Glucose metabolism mediates disease tolerance in cerebral malaria. *Proc*
1288 *Natl Acad Sci U S A* **115**, 11042-11047 (2018).
1289
- 1290 11. Medzhitov, R., Schneider, D.S. & Soares, M.P. Disease tolerance as a defense strategy.
1291 *Science* **335**, 936-941 (2012).
1292
- 1293 12. Ademolue, T.W., Aniweh, Y., Kusi, K.A. & Awandare, G.A. Patterns of inflammatory
1294 responses and parasite tolerance vary with malaria transmission intensity. *Malar J* **16**, 145
1295 (2017).
1296
- 1297 13. Nahrendorf, W., Ivens, A. & Spence, P.J. Inducible mechanisms of disease tolerance provide
1298 an alternative strategy of acquired immunity to malaria. *Elife* **10** (2021).
1299
- 1300 14. Milne, K. *et al.* Mapping immune variation and var gene switching in naive hosts infected
1301 with *Plasmodium falciparum*. *Elife* **10** (2021).
1302
- 1303 15. Stanistic, D.I., McCarthy, J.S. & Good, M.F. Controlled Human Malaria Infection:
1304 Applications, Advances, and Challenges. *Infect Immun* **86** (2018).
1305
- 1306 16. Baird, J.K. *et al.* Adult Javanese migrants to Indonesian Papua at high risk of severe disease
1307 caused by malaria. *Epidemiol Infect* **131**, 791-797 (2003).
1308
- 1309 17. Baird, J.K. *et al.* Age-dependent susceptibility to severe disease with primary exposure to
1310 *Plasmodium falciparum*. *J Infect Dis* **178**, 592-595 (1998).

- 1311
1312 18. Draper, S.J. *et al.* Malaria Vaccines: Recent Advances and New Horizons. *Cell Host Microbe*
1313 **24**, 43-56 (2018).
1314
1315 19. Duncan, C.J. & Draper, S.J. Controlled human blood stage malaria infection: current status
1316 and potential applications. *Am J Trop Med Hyg* **86**, 561-565 (2012).
1317
1318 20. Cheng, Q. *et al.* Measurement of Plasmodium falciparum growth rates in vivo: a test of
1319 malaria vaccines. *Am J Trop Med Hyg* **57**, 495-500 (1997).
1320
1321 21. Spence, P.J. *et al.* Vector transmission regulates immune control of Plasmodium virulence.
1322 *Nature* **498**, 228-231 (2013).
1323
1324 22. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
1325 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
1326
1327 23. Feintuch, C.M. *et al.* Activated Neutrophils Are Associated with Pediatric Cerebral Malaria
1328 Vasculopathy in Malawian Children. *mBio* **7**, e01300-01315 (2016).
1329
1330 24. Loughland, J.R. *et al.* Transcriptional profiling and immunophenotyping show sustained
1331 activation of blood monocytes in subpatent Plasmodium falciparum infection. *Clin Transl*
1332 *Immunology* **9**, e1144 (2020).
1333
1334 25. Antonelli, L.R. *et al.* The CD14+CD16+ inflammatory monocyte subset displays increased
1335 mitochondrial activity and effector function during acute Plasmodium vivax malaria. *PLoS*
1336 *Pathog* **10**, e1004393 (2014).
1337
1338 26. Rocha, B.C. *et al.* Type I Interferon Transcriptional Signature in Neutrophils and Low-Density
1339 Granulocytes Are Associated with Tissue Damage in Malaria. *Cell Rep* **13**, 2829-2841 (2015).
1340
1341 27. Hviid, L. *et al.* Rapid reemergence of T cells into peripheral circulation following treatment
1342 of severe and uncomplicated Plasmodium falciparum malaria. *Infect Immun* **65**, 4090-4093
1343 (1997).
1344
1345 28. Mandala, W.L., Ward, S., Taylor, T.E. & Wassmer, S.C. Characterization of Lymphocyte
1346 Subsets in Lymph Node and Spleen Sections in Fatal Pediatric Malaria. *Pathogens* **11**
1347 (2022).
1348
1349 29. Bach, F.A. *et al.* A systematic analysis of the human immune response to Plasmodium vivax.
1350 *J Clin Invest* **133** (2023).
1351
1352 30. Sharp, P.M., Plenderleith, L.J. & Hahn, B.H. Ape Origins of Human Malaria. *Annu Rev*
1353 *Microbiol* **74**, 39-63 (2020).
1354
1355 31. Carpio, V.H. *et al.* T Helper Plasticity Is Orchestrated by STAT3, Bcl6, and Blimp-1 Balancing
1356 Pathology and Protection in Malaria. *iScience* **23**, 101310 (2020).
1357
1358 32. Stoeckius, M. *et al.* Cell Hashing with barcoded antibodies enables multiplexing and doublet
1359 detection for single cell genomics. *Genome Biol* **19**, 224 (2018).
1360
1361 33. Lonnberg, T. *et al.* Single-cell RNA-seq and computational analysis using temporal mixture
1362 modelling resolves Th1/Tfh fate bifurcation in malaria. *Sci Immunol* **2** (2017).
1363
1364 34. Cao, W. *et al.* TRIB2 safeguards naive T cell homeostasis during aging. *Cell Rep* **42**, 112195
1365 (2023).

- 1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
35. Galletti, G. *et al.* Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans. *Nat Immunol* **21**, 1552-1562 (2020).
 36. Ko, C.J. *et al.* The E3 ubiquitin ligase Peli1 regulates the metabolic actions of mTORC1 to suppress antitumor T cell responses. *EMBO J* **40**, e104532 (2021).
 37. Choi, Y.S. *et al.* LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6. *Nat Immunol* **16**, 980-990 (2015).
 38. Zhao, X., Shan, Q. & Xue, H.H. TCF1 in T cell immunity: a broadened frontier. *Nat Rev Immunol* **22**, 147-157 (2022).
 39. Mathewson, N.D. *et al.* Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. *Cell* **184**, 1281-1298 e1226 (2021).
 40. Ng, S.S. *et al.* The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. *Nat Immunol* **21**, 1205-1218 (2020).
 41. Schober, K. *et al.* Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection. *Nat Immunol* **21**, 434-441 (2020).
 42. Appay, V. *et al.* Characterization of CD4(+) CTLs ex vivo. *J Immunol* **168**, 5954-5958 (2002).
 43. Mattoo, H. *et al.* Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. *J Allergy Clin Immunol* **138**, 825-838 (2016).
 44. Oh, D.Y. *et al.* Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. *Cell* **181**, 1612-1625 e1613 (2020).
 45. Rahil, Z. *et al.* Landscape of coordinated immune responses to H1N1 challenge in humans. *J Clin Invest* **130**, 5800-5816 (2020).
 46. Napolitani, G. *et al.* Clonal analysis of Salmonella-specific effector T cells reveals serovar-specific and cross-reactive T cell responses. *Nat Immunol* **19**, 742-754 (2018).
 47. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140 (2010).
 48. Chughlay, M.F. *et al.* Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection Studies: Findings and Recommendations. *Am J Trop Med Hyg* **103**, 378-393 (2020).
 49. Reuling, I.J. *et al.* Liver Injury in Uncomplicated Malaria is an Overlooked Phenomenon: An Observational Study. *EBioMedicine* **36**, 131-139 (2018).
 50. Woodford, J., Shanks, G.D., Griffin, P., Chalon, S. & McCarthy, J.S. The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. *Am J Trop Med Hyg* **98**, 1113-1119 (2018).
 51. Dudek, M. *et al.* Auto-aggressive CXCR6(+) CD8 T cells cause liver immune pathology in NASH. *Nature* **592**, 444-449 (2021).

- 1420 52. Malaria Genomic Epidemiology, N. Insights into malaria susceptibility using genome-wide
1421 data on 17,000 individuals from Africa, Asia and Oceania. *Nat Commun* **10**, 5732 (2019).
1422
- 1423 53. Patin, E. *et al.* Natural variation in the parameters of innate immune cells is preferentially
1424 driven by genetic factors. *Nat Immunol* **19**, 302-314 (2018).
1425
- 1426 54. Raue, H.P., Beadling, C., Haun, J. & Slifka, M.K. Cytokine-mediated programmed
1427 proliferation of virus-specific CD8(+) memory T cells. *Immunity* **38**, 131-139 (2013).
1428
- 1429 55. Weng, N.P., Liu, K., Catalfamo, M., Li, Y. & Henkart, P.A. IL-15 is a growth factor and an
1430 activator of CD8 memory T cells. *Ann N Y Acad Sci* **975**, 46-56 (2002).
1431
- 1432 56. Greenwood, B.M. Possible role of a B-cell mitogen in hypergammaglobulinaemia in malaria
1433 and trypanosomiasis. *Lancet* **1**, 435-436 (1974).
1434
- 1435 57. Mourao, L.C., Cardoso-Oliveira, G.P. & Braga, E.M. Autoantibodies and Malaria: Where We
1436 Stand? Insights Into Pathogenesis and Protection. *Front Cell Infect Microbiol* **10**, 262 (2020).
1437
- 1438 58. Welsh, R.M. & Selin, L.K. No one is naive: the significance of heterologous T-cell immunity.
1439 *Nat Rev Immunol* **2**, 417-426 (2002).
1440
- 1441 59. Bernabeu, M. *et al.* Binding Heterogeneity of Plasmodium falciparum to Engineered 3D Brain
1442 Microvessels Is Mediated by EPCR and ICAM-1. *mBio* **10** (2019).
1443
- 1444 60. Riggle, B.A. *et al.* CD8+ T cells target cerebrovasculature in children with cerebral malaria.
1445 *J Clin Invest* **130**, 1128-1138 (2020).
1446
- 1447 61. Wassmer, S.C., de Koning-Ward, T.F., Grau, G.E.R. & Pai, S. Unravelling mysteries at the
1448 perivascular space: a new rationale for cerebral malaria pathogenesis. *Trends Parasitol* **40**,
1449 28-44 (2024).
1450
- 1451 62. Crispe, I.N., Dao, T., Klugewitz, K., Mehal, W.Z. & Metz, D.P. The liver as a site of T-cell
1452 apoptosis: graveyard, or killing field? *Immunol Rev* **174**, 47-62 (2000).
1453
- 1454 63. Noe, A. *et al.* Deep Immune Phenotyping and Single-Cell Transcriptomics Allow
1455 Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and
1456 Vaccine-Induced Protection From Malaria. *Front Immunol* **13**, 795463 (2022).
1457
- 1458 64. Edwards, C.L. *et al.* IL-10-producing Th1 cells possess a distinct molecular signature in
1459 malaria. *J Clin Invest* **133** (2023).
1460
- 1461 65. Jagannathan, P. *et al.* IFN γ /IL-10 co-producing cells dominate the CD4 response to
1462 malaria in highly exposed children. *PLoS Pathog* **10**, e1003864 (2014).
1463
- 1464 66. Walther, M. *et al.* Distinct roles for FOXP3+ and FOXP3- CD4 T cells in regulating cellular
1465 immunity to uncomplicated and severe Plasmodium falciparum malaria. *PLoS Pathog* **5**,
1466 e1000364 (2009).
1467
- 1468 67. Newton, P.N. *et al.* A comparison of the in vivo kinetics of Plasmodium falciparum ring-
1469 infected erythrocyte surface antigen-positive and -negative erythrocytes. *Blood* **98**, 450-457
1470 (2001).
1471
- 1472 68. Heesters, B.A. *et al.* Characterization of human FDCs reveals regulation of T cells and
1473 antigen presentation to B cells. *J Exp Med* **218** (2021).
1474

- 1475 69. Clark, H.C. & Tomlinson, W.J. The pathologic anatomy of malaria. *Malaria* **2**, 874-903
1476 (1949).
1477
- 1478 70. Osii, R.S., Otto, T.D., Garside, P., Ndungu, F.M. & Brewer, J.M. The Impact of Malaria
1479 Parasites on Dendritic Cell-T Cell Interaction. *Front Immunol* **11**, 1597 (2020).
1480
- 1481 71. Snell, L.M. *et al.* CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially
1482 Directs Differentiation of Memory-like Cells for Sustained Immunity. *Immunity* **49**, 678-694
1483 e675 (2018).
1484
- 1485 72. Zou, D. *et al.* CD4+ T cell immunity is dependent on an intrinsic stem-like program. *Nat*
1486 *Immunol* **25**, 66-76 (2024).
1487
- 1488 73. Nish, S.A. *et al.* CD4+ T cell effector commitment coupled to self-renewal by asymmetric
1489 cell divisions. *J Exp Med* **214**, 39-47 (2017).
1490
- 1491 74. Xu, L. *et al.* The transcription factor TCF-1 initiates the differentiation of TFH cells during
1492 acute viral infection. *Nat Immunol* **16**, 991-999 (2015).
1493
- 1494 75. Kimingi, H.W. *et al.* Breadth of Antibodies to Plasmodium falciparum Variant Surface
1495 Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study. *Front*
1496 *Immunol* **13**, 894770 (2022).
1497
- 1498 76. Osier, F.H. *et al.* Breadth and magnitude of antibody responses to multiple Plasmodium
1499 falciparum merozoite antigens are associated with protection from clinical malaria. *Infect*
1500 *Immun* **76**, 2240-2248 (2008).
1501
- 1502 77. Rono, J. *et al.* Breadth of anti-merozoite antibody responses is associated with the genetic
1503 diversity of asymptomatic Plasmodium falciparum infections and protection against clinical
1504 malaria. *Clin Infect Dis* **57**, 1409-1416 (2013).
1505
- 1506 78. Furtado, R. *et al.* Cytolytic memory CD4+ T cell clonotypes are expanded during
1507 *Plasmodium falciparum* infection. *bioRxiv*, 2021.2007.2021.453277 (2021).
1508
- 1509 79. de Jong, S.E. *et al.* Systems analysis and controlled malaria infection in Europeans and
1510 Africans elucidate naturally acquired immunity. *Nat Immunol* **22**, 654-665 (2021).
1511
- 1512 80. Soon, M.S.F. *et al.* Transcriptome dynamics of CD4(+) T cells during malaria maps gradual
1513 transit from effector to memory. *Nat Immunol* **21**, 1597-1610 (2020).
1514
- 1515 81. Minassian, A.M. *et al.* Reduced blood-stage malaria growth and immune correlates in
1516 humans following RH5 vaccination. *Med (N Y)* **2**, 701-719 (2021).
1517
- 1518 82. Salkeld, J. *et al.* Repeat controlled human malaria infection of healthy UK adults with blood-
1519 stage Plasmodium falciparum: Safety and parasite growth dynamics. *Front Immunol* **13**,
1520 984323 (2022).
1521
- 1522 83. Payne, R.O. *et al.* Demonstration of the Blood-Stage Plasmodium falciparum Controlled
1523 Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane
1524 Antigen 1 Vaccine, FMP2.1/AS01. *J Infect Dis* **213**, 1743-1751 (2016).
1525
- 1526 84. Minassian, A.M. *et al.* Controlled human malaria infection with a clone of Plasmodium vivax
1527 with high-quality genome assembly. *JCI Insight* **6** (2021).
1528

- 1529 85. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**,
1530 357-359 (2012).
1531
- 1532 86. Harrington, C.A. *et al.* RNA-Seq of human whole blood: Evaluation of globin RNA depletion
1533 on Ribo-Zero library method. *Sci Rep* **10**, 6271 (2020).
1534
- 1535 87. Shin, H. *et al.* Variation in RNA-Seq transcriptome profiles of peripheral whole blood from
1536 healthy individuals with and without globin depletion. *PLoS One* **9**, e91041 (2014).
1537
- 1538 88. Wickam, H. ggplot2: Elegant Graphics for Data Analysis. *Springer-Verlag New York* (2016).
1539
- 1540 89. Mizuno, H., Nakanishi, Y., Ishii, N., Sarai, A. & Kitada, K. A signature-based method for
1541 indexing cell cycle phase distribution from microarray profiles. *BMC Genomics* **10**, 137
1542 (2009).
1543
- 1544 90. Pena-Diaz, J. *et al.* Transcription profiling during the cell cycle shows that a subset of
1545 Polycomb-targeted genes is upregulated during DNA replication. *Nucleic Acids Res* **41**,
1546 2846-2856 (2013).
1547
- 1548 91. Dominguez, D. *et al.* A high-resolution transcriptome map of cell cycle reveals novel
1549 connections between periodic genes and cancer. *Cell Res* **26**, 946-962 (2016).
1550
- 1551 92. Giotti, B., Joshi, A. & Freeman, T.C. Meta-analysis reveals conserved cell cycle
1552 transcriptional network across multiple human cell types. *BMC Genomics* **18**, 30 (2017).
1553
- 1554 93. Bindea, G. *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene
1555 ontology and pathway annotation networks. *Bioinformatics* **25**, 1091-1093 (2009).
1556
- 1557 94. Mlecnik, B. *et al.* Functional network pipeline reveals genetic determinants associated with
1558 in situ lymphocyte proliferation and survival of cancer patients. *Sci Transl Med* **6**, 228ra237
1559 (2014).
1560
- 1561 95. Chomczynski, P. & Sacchi, N. The single-step method of RNA isolation by acid guanidinium
1562 thiocyanate-phenol-chloroform extraction: twenty-something years on. *Nat Protoc* **1**, 581-
1563 585 (2006).
1564
- 1565 96. Mamedov, I.Z. *et al.* Preparing unbiased T-cell receptor and antibody cDNA libraries for the
1566 deep next generation sequencing profiling. *Front Immunol* **4**, 456 (2013).
1567
- 1568 97. Shugay, M. *et al.* Towards error-free profiling of immune repertoires. *Nat Methods* **11**, 653-
1569 655 (2014).
1570
- 1571 98. Bolotin, D.A. *et al.* MiXCR: software for comprehensive adaptive immunity profiling. *Nat*
1572 *Methods* **12**, 380-381 (2015).
1573
- 1574 99. Lefranc, M.P. *et al.* IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res*
1575 **27**, 209-212 (1999).
1576
- 1577 100. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony.
1578 *Nat Methods* **16**, 1289-1296 (2019).
1579
- 1580 101. Street, K. *et al.* Slingshot: cell lineage and pseudotime inference for single-cell
1581 transcriptomics. *BMC Genomics* **19**, 477 (2018).
1582

- 1583 102. Borcharding, N., Bormann, N.L. & Kraus, G. scRepertoire: An R-based toolkit for single-cell
1584 immune receptor analysis. *F1000Res* **9**, 47 (2020).
1585
- 1586 103. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in
1587 multidimensional genomic data. *Bioinformatics* **32**, 2847-2849 (2016).
1588
- 1589 104. Finck, R. *et al.* Normalization of mass cytometry data with bead standards. *Cytometry A* **83**,
1590 483-494 (2013).
1591
- 1592 105. Zunder, E.R. *et al.* Palladium-based mass tag cell barcoding with a doublet-filtering scheme
1593 and single-cell deconvolution algorithm. *Nat Protoc* **10**, 316-333 (2015).
1594
- 1595 106. Crowell, H., Zanotelli, V., Chevrier, S. & Robinson, M. CATALYST: Cytometry dATa
1596 anALYSIS Tools. *R/Bioconductor version 1.14.0* (2020).
1597
- 1598 107. Chevrier, S. *et al.* Compensation of Signal Spillover in Suspension and Imaging Mass
1599 Cytometry. *Cell Syst* **6**, 612-620 e615 (2018).
1600
- 1601 108. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection
1602 for Dimension Reduction. *arXiv:1802.03426* (2020).
1603
- 1604 109. McCarthy, D.J., Campbell, K.R., Lun, A.T. & Wills, Q.F. Scater: pre-processing, quality
1605 control, normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics* **33**,
1606 1179-1186 (2017).
1607
- 1608 110. Van Gassen, S. *et al.* FlowSOM: Using self-organizing maps for visualization and
1609 interpretation of cytometry data. *Cytometry A* **87**, 636-645 (2015).
1610
- 1611 111. Saeys, Y., Van Gassen, S. & Lambrecht, B. Response to Orlova *et al.* "Science not art:
1612 statistically sound methods for identifying subsets in multi-dimensional flow and mass
1613 cytometry data sets". *Nat Rev Immunol* **18**, 78 (2017).
1614
- 1615 112. Nowicka, M. *et al.* CyTOF workflow: differential discovery in high-throughput high-
1616 dimensional cytometry datasets. *F1000Res* **6**, 748 (2017).
1617
- 1618 113. Weber, L.M., Nowicka, M., Soneson, C. & Robinson, M.D. diffcyt: Differential discovery in
1619 high-dimensional cytometry via high-resolution clustering. *Commun Biol* **2**, 183 (2019).